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Summary
Accurately estimating a patient’s risk of experiencing side effects from radiation ther-
apy is crucial for safe and effective treatment. Normal tissue complication probabil-
ity (NTCP) models are tools that predict a patient’s probability of experiencing side
effects, depending on the dose received by organs at risk. The following thesis inves-
tigates the influence of treatment technique, fractionation and dose calculation algo-
rithms on NTCP models, and shows that common NTCP models cannot be applied to
different treatment techniques, fractionation schemes and dose calculation algorithms
because they yield different model parameters depending on these factors.
In order to investigate how the treatment technique influences NTCP modelling re-
sults, NTCP model parameters for chronic gastrointestinal toxicities following prostate
cancer treatment for patients treated with three dimensional conformal radiation ther-
apy (3D-CRT) and intensity modulated radiation therapy (IMRT) are derived and com-
pared. The 3D-CRT and IMRT patients are matched using propensity score matched
pair analysis to reduce potential bias from confounding variables. It is shown that the
models derived from the 3D-CRT and the IMRT populations were not cross-applicable.
These results are unexpected, since NTCP model parameters for a clinical endpoint
should ideally be independent of the treatment technique. Investigations into the po-
tential sources of discrepancies between optimal model parameters for the two groups
ruled out differences in follow-up time, imaging modalities used, known patient char-
acteristics, and errors of planned versus delivered dose. Other potential sources of the
discrepancies are discussed and may be related to the toxicity scoring, confounding
patient characteristics not accounted for by matched pair analysis, and insufficiency
of the NTCP models themselves.
Subsequently, the NTCP of developing radiation pneumonitis in lung cancer pa-
tients treated with hypofractionated radiation therapy (HFRT) is modelled. In order
to account for different fractionation schemes, the linear quadratic (LQ) model and
the low dose hyperradiosensitivity model (LDHRS) are used to adjust the physical
dose accordingly. NTCP is modelled and compared using both biological models.
The NTCP model parameters for HFRT using the LQ model differ from parameters
that were previously derived for standard fractionated radiation therapy (SFRT) in
the literature. Thus, it is demonstrated that NTCP models are not cross applicable for
different fractionation schemes, even when accounting for differences in fractionation
using the LQ model. Furthermore, novel NTCP parameters using the LDHRS model
are provided and the feasibility of using the LDHRS model for modelling NTCP of ra-
ix
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diation pneumonitis for lung HFRT is demonstrated. It is discussed how the LDHRS
model could potentially be used to find a common NTCP model for radiation pneu-
monitis in HFRT and SFRT lung cancer patients, although this will have to be verified
in future studies.
Moreover, since it was observed in previous publications that HFRT in lung leads
to increased incidences of toxicities related to the chest wall, NTCP model parameters
for chest wall pain, rib fractures, and myositis are determined and discussed in this
work.
Lastly, it is demonstrated that the choice of dose calculation algorithm significantly
impacts dose volume parameters for regions of interest. Pencil beam (PB) and col-
lapsed cone (CC) based dose calculation algorithms are compared for lung stereotac-
tic body radiation therapy. It is shown that using CC to recalculate dose in lung plans
created with PB leads to drastic differences in the planned dose in regions of inter-
est. Since accurate dose distributions are vital in NTCP modelling, these discrepancies
could lead to differences in NTCP model parameters.
x
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Zusammenfassung
Die akkurate Einschätzung von Nebenwirkungswahrscheinlichkeiten in der Strahlen-
therapie ist essentiell um eine sichere und effektive Behandlung sicherzustellen. Nor-
mal tissue complication probability (NTCP) Modelle sind eine Methode für die Vorher-
sage der Wahrscheinlichkeit, dass ein Patient Nebenwirkungen erfährt in Abhängigkeit
von der Dosis in Risikoorganen. Die vorliegende Arbeit befasst sich mit dem Einfluss
der Behandlungstechnik, der Fraktionierung und des Dosisberechnungsalgorithmus
auf NTCP-Modelle. Es wird gezeigt, dass verbreitete NTCP-Modelle nicht auf an-
dere Behandlungstechniken, Fraktionierungsschemata und Pläne, die mit anderen Do-
sisberechnungsalgorithmen berechnet wurden, angewendet werden können, da die
Modellparameter von diesen Faktoren abhängig sind.
Um zu untersuchen, inwiefern die Behandlungstechnik Ergebnisse der NTCP Mod-
ellierung beeinflusst, werden NTCP Modellparameter für chronische gastrointestinale
Toxizitäten, welche nach der Behandlung von Prostatakarzinomen auftreten können,
für dreidimensionale konformale Strahlentherapie (3D-CRT) und intensitätsmodulierte
Strahlentherapie (IMRT) bestimmt und verglichen. Die 3D-CRT und IMRT Patien-
tendatensätze werden einander mittels eines Matchingalgorithmuses statistisch zu-
geordnet, um den Einfluss von potenziellen Störfaktoren wie beispielsweise unter-
schiedliche Populationscharakteristiken zu reduzieren. Es wird gezeigt, dass Modell-
parameter, die mittels des 3D-CRT Datensatzes bestimmt wurden, nicht auf den IMRT
Datensatz angewendet werden können und umgekehrt. Diese Ergebnisse sind uner-
wartet, da die NTCP-Modellparameter für einen spezifischen klinischen Endpunkt
idealerweise nicht von der Behandlungstechnik abhängig sein sollte. Durch weitere
Nachforschung konnten unterschiedliche Nachsorgezeitspannen, Bildgebungsmetho-
den, bekannte Populationcharakteristiken und Diskrepanzen zwischen geplanter und
abgestrahlter Dosis als potenzielle Ursachen für die unterschiedlichen Modellpara-
meter ausgeschloßen werden. Weitere mögliche Ursachen für die Diskrepanzen zwis-
chen den beiden Behandlungstechniken, einschließlich der Subjektivität der Bewer-
tung von Toxizitäten, Patientencharakteristiken, die beim Matching nicht berücksichtigt
werden konnten, und Modellbeschränkungen der NTCP Modelle, werden diskutiert.
Nachfolgend wird NTCP für Pneumonitis in Lungenkrebspatienten, welche mit
hypofraktionierter Strahlentherapie (HFRT) behandelt wurden, modelliert. Dabei wer-
den zwei biologische Modelle, das linearquadratische Modell und das low dose hy-
perradiosensitivity model (LDHRS), benutzt um die biologischen Auswirkungen ver-
schiedener Fraktionierungsschemata zu berücksichtigen und die physikalische Dosis
xi
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entsprechend anzupassen. NTCP wird für beide Modelle modelliert und verglichen.
Die Ergebnisse zeigen, dass NTCP-Modellparameter für HFRT, die mittels des LQ-
Modelles bestimmt wurden, nicht mit den Werten, die in der Literatur für standard-
fraktionierte Strahlentherapie (SFRT) angegeben sind, übereinstimmen. Damit wird
auch gezeigt, dass NTCP-Modelle nicht ohne Weiteres auf andere Fraktionierungs-
schemata angewendet werden können, wenn das LQ-Modell benutzt wird. Des Wei-
teren werden neue NTCP-Modellparameter für Fraktionskorrektur mittels des LDHRS-
Modells bestimmt und die grundsätzliche Machbarkeit der NTCP-Modellierung mit
dem LDHRS-Modell für hypofraktionierte Bestrahlung der Lungen wird demonstriert.
Anschließend wird diskutiert, dass das LDHRS-Modell potenziell verwendet werden
kann um ein gemeinsames Pneumonitis NTCP-Modell für HFRT uns SFRT in der
Lunge zu finden. Dies muss jedoch in zukünftigen Studien verifiziert werden.
Des Weiteren wurde in früheren Studien festgestellt, dass HFRT in der Lunge zu
einem Anstieg der Inzidenz von Toxitäten der Thoraxwand führt. Daher werden in
der vorliegenden Arbeit NTCP-Modellparameter für Schmerzen in der Thoraxwand,
Rippenfrakturen und Myositis bestimmt und diskutiert.
Zuletzt wird gezeigt, dass die Wahl des Dosisberechnungsalgorithmuses Dosisvo-
lumenparameter für Tumore und Risikoorgane stark beeinflussen kann. Dosisberech-
nungen für Lungenstereotaxien basierend auf Pencil Beam (PB) und Collapsed Cone
Algorithmen werden verglichen. Es wird gezeigt, dass die Nachrechnung von Plänen
mit CC, die ursprünglich mit PB berechnet wurden, zu drastischen Unterschieden in
der Plandosis führen können. Da die Qualität der NTCP-Modellierung auf akkuraten
Dosisberechnungen beruht, können diese Dosisunterschiede zu unterschiedlichen NTCP-
Modellparametern führen.
xii
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Chapter 1
Introduction
The successful treatment of cancer is one of the modern world’s major medical chal-
lenges. According to the 2014 World Cancer Report by the World Health Organiza-
tion, there were an estimated 14 million new cases of cancer worldwide in 2012, with
lung, liver, stomach, colorectal and breast cancers as the leading cause of cancer deaths
(Stewart et al., 2014). Radiation therapy (RT) has been used to treat cancer since the
early 20th century when the lethal effects of radiation on tissue were first discovered.
Since then, radiation therapy has significantly improved and shown impressive out-
comes, especially in combination with other treatment modalities such as surgery and
chemotherapy. Today, local control and overall survival rate are significantly higher
for many types of cancer than they were in the 1930s, when radiation therapy was lim-
ited to curing a small range of cancers such as skin or uterus cancer (Thariat et al., 2012).
In contrast, today a wider variety of cancers can be treated with RT such as breast can-
cer, lung cancer, prostate cancer, lymphomas, brain, head and neck and many other
types. The overall survival rate 5 years after diagnosis for some cancers commonly
treated with RT, for example prostate cancer, can be as high as 98.9% (Bethesda, 2014).
While the main goal of RT is to irradiate the tumor and gain tumor control, this is
achieved at the expense of normal tissue damage. Irradiation of normal tissues can
lead to severe side effects that can impact the patient’s quality of life or even have
lethal consequences. Thus, it is imperative to spare normal tissues during treatment.
Since uncertainties such as finite dose gradients, anatomical changes, movement, po-
sitioning errors, and microscopic disease prevent sufficient irradiation of tumor cells
without irradiating normal tissues, it is crucial to RT that complication probabilities of
organs at risk (OARs) are accurately assessed and guidelines for which doses OARs
can tolerate are established. Until recent years, physicians heavily depended on pub-
lished guidelines by Emami et al. (Emami et al., 1991) in order to estimate normal tissue
complication probability (NTCP) for OARs. However, Emami’s guidelines are based
on older treatment techniques using either homogeneous whole organ irradiation or
homogeneous irradiation of partial organs. Furthermore, these values are based on
physicians’ clinical experience, rather than models and predictions derived from care-
fully collected and analyzed scientific data. Recent treatment plans are more complex
and involve a high degree of heterogeneity. Thus more elaborate and objective mea-
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sures for predicting complications are needed. NTCP modelling derives a model from
treatment data and outcome of a large population that can then be applied to a pa-
tient to be treated. An NTCP model assigns a complication probability for a certain
endpoint to an inhomogeneous dose distribution of an OAR. One of the first NTCP
models was proposed by Lyman (Lyman, 1985) and extended by Kutcher and Burman
(Kutcher and Burman, 1989) in the 1980s and 1990s. At that time, the models were
limited due to the limited availability of data used, and the lack of computational
power. Since then various NTCP models have been established and are successfully
being used in the clinic (Marks et al., 2010). However, the field of NTCP modelling
also faces several challenges. Among these challenges are issues of model extrapo-
lation to populations with different population characteristics, fractionation schemes,
treatment techniques etc.
The aim of this thesis is to investigate some of the challenges and uncertainties
that NTCP modelling faces, namely to investigate how treatment modalities, fraction-
ation and the choice of dose calculation algorithms influence dose to regions of interest
(ROIs) and NTCP models:
1. Applicability of NTCP models to other treatment techniques: Radiation ther-
apy is a rapidly evolving field in which new treatment techniques are constantly
incorporated into the clinical routine. In recent years intensity modulated ra-
diation therapy (IMRT) and volumetric modulated arc therapy (VMAT) have
been implemented in many clinical facilities. Since successful NTCP modelling
requires accumulating data from large patient cohorts, many NTCP model pa-
rameters used in the clinic are derived from older treatment techniques, such as
three dimensional conformal radiation therapy (3D-CRT) for which large patient
populations are available for modelling. However, using NTCP parameters de-
rived from a population treated with one treatment technique to patients treated
with a different technique can be problematic. For example, the patient popu-
lations may differ in patient characteristics that influence the incidence of side
effects, such as smoking or patient age. Differences in model parameters could
also arise for instance because of advanced imaging technology being developed
contemporaneously with newer treatment techniques. In chapter 5 of this thesis,
the effect of different treatment modalities on the outcomes of NTCP modelling
is investigated. Specifically, NTCP is modelled for two matched groups of pa-
tients treated with 3D-CRT and IMRT, respectively. The model parameters are
compared and it is determined whether one set of model parameters is able to
predict NTCP for the other and vice versa. Furthermore, the influence of con-
founding patient characteristics, actual delivered dose, and toxicity scoring bias
on NTCP modelling is explored and discussed.
2. Implications of fractionation schemes on NTCP models: Fractionation of the
dose delivered during radiation therapy was introduced in order to spare OARs.
It is based on research indicating that with the ability to divide in an uncontrolled
manner, tumor cells have lost some of their repair capabilities, while normal
tissues retain the ability to repair. Delivering the full treatment dose in fractions
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allows healthy tissues to recover while still destroying tumor cells. However,
more recently, larger fractions are being delivered without markedly increasing
normal tissue damage. Chapter 6 explores the effect of fractionation schemes on
NTCP modelling of radiation pneumonitis. It investigates different biological
models accounting for fractionation effects and their potential to be applied to
alternative fractionation schemes. Furthermore, different fractionation schemes
may lead to the incidence of different side effects which require novel NTCP
models parameters. In section 6.3, models for side effects emerging from the
chest wall are presented.
3. Importance of dose calculation algorithms on organs at risk and tumor dose:
The basis of all NTCP models is the assumption that a patient’s probability of
experiencing side effects is a function of the dose delivered to tissue. Thus, in
order to develop accurate NTCP models, it is of importance that the dose distri-
bution used for modelling is correct. In practice, the dose delivered to the patient
cannot be measured, but must be calculated. However, the dose calculation itself
yields errors. In the past, most commercial treatment planning systems (TPSs)
used pencil beam (PB) algorithms to approximately calculate dose. Since then
more accurate methods of calculating dose, such as collapsed cone (CC) based
algorithms and highly accurate Monte Carlo (MC) based methods have been
implemented into clinically used TPSs. However, many dose constraints and
dose response models for ROIs are derived from treatment plans calculated us-
ing PB algorithms. Thus, they do not necessarily reflect the best constraints and
model parameters for plans calculated with CC or MC. It is therefore important
to determine how the choice of the dose calculation algorithm affects the planned
dose. In chapter 7 the effect of using PB and CC dose calculation algorithms on
both normal tissues and tumor tissues is discussed.
Chapter 2 contains basic background information on the major physical principles
used in RT including a brief introduction of medical linear accelerators, the interaction
of X-rays with matter, and dose. In chapter 3, the treatment planning process including
dose calculation algorithms is described and chapter 4 introduces methods used in
NTCP modelling. The influences of the treatment technique, fractionation scheme,
and the choice of dose calculation algorithms on NTCP models are investigated in
chapter 5, chapter 6, and chapter 7, respectively. Finally, the conclusions of this thesis
are discussed in chapter 8.
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Chapter 2
Physics of Radiation Therapy
In radiotherapy, malignant tumors are treated with ionizing radiation in order to de-
stroy or inactivate tumor cells. This is achieved by the ionization of tumor deoxyri-
bonucleic acid (DNA) by either photons, or charged particles such as electrons, pro-
tons or heavier ions. Ionization of the DNA strands, in turn, may lead to double strand
breaks in the cell DNA, which are difficult to repair and can lead to cell death. While
photons act mostly indirectly via ionization of water in the patient’s body forming free
radicals, charged particles may damage DNA directly.
This chapter focuses on the utilization of high energy photon beams that are pro-
duced by medical linear accelerators (LINACs) and then interact with tissue, thereby
damaging or destroying cells. While other photon based techniques in radiation ther-
apy (such as gamma rays from radioactive isotopes like 60Co), and also charged parti-
cle radiation therapy are all important methods of treatment, all patients presented in
this thesis were treated using photon beams from medical LINACs. Therefore, the the-
sis focuses on the production and interaction of photon beams from medical LINACs.
A picture of the front of a medical LINAC is shown in Figure 2.1. The photon beam
produced by the LINAC travels from the LINAC head through air and eventually
strikes the patient. In the patient the photons interact with the tissue matter and the
beam is attenuated via scattering and absorption thereby producing high energy elec-
trons. Thus, the photons transfer their energy to charged particles (electrons) which in
turn transfer their kinetic energy to the tissue via excitation and ionization. As men-
tioned above, this energy can be sufficient to break or inactivate cells and is the basic
means of destroying tumor cells in radiotherapy. The patient is positioned on a couch
which can usually perform translational movements in three dimensions as well as
rotate around at least one axis. In combination with the rotation of the gantry (from
which the beam emerges), this enables the photon beam to irradiate the patient from
virtually all angles.
In the following sections, X-ray production using a LINAC is described (2.1), fol-
lowed by a brief description of the resulting photon beam (2.2). Interactions of X-ray
photons with matter are then discussed (2.3), as well as ionization, excitation, energy
deposition and absorbed dose (2.4). More detailed information can be found in the
standard literature e.g. (Metcalfe et al., 1997; Khan, 2010; Krieger, 2012).
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Figure 2.1: The front of a medical linear accelerator (LINAC) including the couch on
which the patient is positioned. Image courtesy of Elekta (www.elekta.com, Stock-
holm, Sweden).
2.1 Photon Production with Medical Linear Accelerators
A medical LINAC produces X-ray photons by accelerating electrons which then strike
a target. The electrons are accelerated in a high frequency electromagnetic field. A
typical medical LINAC uses a magnetron or klystron to generate microwaves in a
waveguide accelerator. An electron gun then inserts low energy electrons into the
waveguide which are accelerated to very high velocities near the speed of light. When
the high energy electrons leave the waveguide, they are usually bent into the final
direction of the beam by a bending magnet and eventually hit a small target thereby
producing bremsstrahlung X-rays. The X-rays then travel through the treatment head
and eventually strike the patient. In the following the major components of LINACs
are briefly discussed. A schematic diagram of a LINAC is shown in Figure 2.2a.
2.1.1 Electron Source
The electron gun is the LINAC’s source of low speed electrons. It consist of a tungsten
cathode and an anode in a vacuum tube. The cathode is heated to high temperatures
(T > 1000◦C) in order to produce free electrons via thermionic emission. These free
electrons are then accelerated by the electric field between the cathode and the anode.
Typical electron guns operate at 30-100 kV. At the anode, the electrons are inserted into
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the acceleration waveguide of the LINAC.
2.1.2 Microwave Production
The microwaves in linear accelerators are produced by either a klystron or a mag-
netron. Klystrons do not generate microwaves but rather amplify an existing mi-
crowave. They consist of an electron gun that generates an electron beam which then
passes through a buncher and a catcher cavity that both resonate at the frequency of
the low power microwave to be amplified. The low power microwave is fed into the
buncher cavity, where it generates an oscillating electric field in the path of the elec-
tron beam. Electrons that pass through the cavity become velocity modulated. That
is, electrons that pass the cavity while the electric field points in the same direction
as the electron flow will be decelerated, whereas electrons passing through the cav-
ity when the electric field points in the opposite direction will be accelerated. The
electrons then enter a drifting space in between the buncher cavity and the catcher
cavity, where they form bunches due to the acceleration and deceleration they experi-
enced in the buncher cavity. The distance between the cavities is designed such that
the electrons pass through the second cavity when they are maximally bunched. At
the catcher cavity, they induce a retarding electric field that decelerates the electron
bunches, thereby producing high power microwave oscillations in the cavity. These
microwaves are of the same frequency as the initial low power microwaves. In con-
trast to klystrons, magnetrons produce microwaves rather than amplifying existing
microwaves. A magnetron consist of a cylindrical copper anode with several holes
(cavities) and a heated cathode at the center of the cylinder. The cathode emits elec-
trons via thermionic emission and a direct current (DC) electric field between the cath-
ode and the anode combined with an external static magnetic field perpendicular to
the magnetron cross section causes them to travel towards the anode in a circular path.
The magnetron is tuned such that the electrons do not initially reach the anode but
pass it closely in a circular motion and then move back towards the cathode. The holes
in the anode are connected to the evacuated space in between the anode and the cath-
ode via small slits that act as capacitors, while the cavities themselves form one loop
induction coils. Thus the sections of the anode can act as parallel resonant circuits
which resonate at microwave frequencies. When the spiralling electrons pass the cav-
ity slits in the anode, they induce an alternating current (AC) electric field across the
anode slits by transferring some of the energy of the DC field. This AC field in turn
velocity modulates the electrons and bunches them based on the same principles as
the klystron leading to a stronger AC field which generates microwaves in the an-
ode cavities. In medical LINACs, magnetrons create pulsed microwaves of about 3000
MHz.
2.1.3 Acceleration and Bending Magnet
The microwaves produced by the klystron or magnetron are eventually fed into the
accelerating waveguide of the medical LINAC where they are used to accelerate the
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electrons inserted by the electron guns. The waveguide consist of several copper cav-
ities in which the electrons are bunched and reach near speed of light velocity. Some
current LINACs have travelling waveguides, where the microwaves enter on one side
and leave on the other. A more efficient approach are standing waveguides where the
microwaves are reflected at the end and create a standing wave. More details on the
principles of waveguides in LINACs can be found for example in (Khan, 2010; Krieger,
2012). After the electron beam leaves the waveguide it needs to be bent towards the
patient (see Figure 2.2a). This is accomplished by using a bending magnet. However,
electrons of different energies follow different paths through the field of a bending
magnet and thus the electron beam will diverge after deflection by a single 90◦ bend-
ing magnet. Therefore, either three 90◦ bending magnets bending the beam by 270◦,
or two 44◦ magnets in combination with one 112◦ magnet that bend the beam along a
snake like curve are typically used in LINACs to allow refocusing the electron beam.
2.1.4 Treatment Head
The treatment head consists of several components that shape and monitor the beam,
such as the X-ray target, a flattening filter, ion chambers and collimators (Figure 2.2b).
The target is made of tungsten and emits bremsstrahlung and characteristic X-rays
when the high energy electrons collide with it. Bremsstrahlung is generated when the
incoming electrons are deflected by fields of the target nuclei and experience decel-
eration. The consequent loss of kinetic energy is compensated by the production of
photons. The angular distribution of photons depends on the energy of the electrons
striking the target. At higher photon energies of at least a few hundred kV, the major-
ity of photons are emitted in the forward direction while at lower energies (e.g. 100
kV) photons are emitted more laterally. Bremsstrahlung has a continuous spectrum
with energies up to the initial kinetic electron energy since the electrons may lose all
or part of their energy in the process. Just below the target is a fixed primary collima-
tor that prevents leakage followed by a flattening filter. The flattening filter is used to
obtain a uniform beam profile. However, the filter, usually composed of steel, copper
or tungsten, leads to significant attenuation. Since in recent radiotherapy the beam
fluence is often modulated, flattening filters may be omitted in favor of a higher dose
rate. The flattening filter also leads to changes in the (angular) energy spectrum of the
beam, because the mass attenuation coefficient depends on the energy of the photons.
Lower energy photons are attenuated more easily than higher energy photons, which
leads to an increase in the average energy of the photon beam. This effect is called
’beam hardening’. Beam hardening also occurs when the photon beam interacts with
the patient’s tissues. Below the flattening filter are ion chambers that monitor dose
rate, beam symmetry and beam homogeneity. Below are four or two movable lead or
tungsten jaws that can create a rectangular opening. In addition to the jaws, modern
LINACs have multi leaf collimators (MLCs) in order to create irregular field shapes.
The treatment had can be rotated along the central beam axis. Finally, the treatment
head is surrounded by thick shielding that prevents X-rays from leaking.
10
2.2. Photon Beam
Waveguide 
Gantry
Microwave 
Generator/
Ampli er
Treatment
Head
Electron BeamElectron
Gun
Bending
Magnets
Photon
Beam
(a) LINAC body.
Electron Beam
Target
Primary Collimators
Flattening Filter
Secondary Collimators
(Jaws)
MLCs
(b) Treatment head of a medical
LINAC.
Figure 2.2: Simplified schematic view of a medical linear accelerator (LINAC).
2.2 Photon Beam
The photon beam that leaves the LINAC is commonly described in terms of fluence
and energy fluence. Fluence is defined as the number of photons N passing through a
cross sectional unit area A
Φ =
dN
dA
. (2.1)
Since the X-ray beam is polyenergetic, the total fluence is an integral
Φ =
∫ Emax
0
∂Φ(E)
∂E
dE (2.2)
Energy fluence is the energy passing through dA
Ψ =
dE
dA
. (2.3)
Once the photon beam strikes a medium it will be attenuated. The interaction cross
section σ describes the probability that a photon striking within a unit cross sectional
area will interact; and the attenuation coefficient µ describes the attenuation of the
photon beam. Since µ is dependent on the density of the material, the mass attenuation
coefficient µ
ρ
is often used, which depends on the atomic properties of the medium and
the photon energy, and is independent of density.
2.3 Interaction of X-Ray Photons with Matter
There are three major types of interaction of X-rays with matter that attenuate the pho-
ton beam generated by the LINAC. The photons can be absorbed via (1) the photoelec-
tric effect, and (2) pair production, or they can be scattered via (3) Compton scattering.
Coherent scattering may also occur, but is important only at low energies and high Z
materials and is not usually relevant for radiotherapy. Each interaction attenuates the
photon beam and is associated with an interaction cross section and an attenuation
coefficient.
11
Chapter 2. Physics of Radiation Therapy
Ep
Ek
Ep′
Figure 2.3: Schematic of Compton scattering.
2.3.1 Compton Scattering
Compton scattering occurs when the incoming photon interacts with an outer shell
electron and transfers part of its energy to the electron (Figure 2.3). In order for Comp-
ton scattering to happen, the energy of the incident photon must be much larger than
the binding energy of the electron, such that the electron can be assumed to be a free
electron in first approximation. After the interaction with the photon, the electron ac-
quires kinetic energy Ekin. The photon’s energy after the collision can be calculated as
Ep′ = Ep − Ekin − Eb, (2.4)
where Ep is the photon’s original energy, Ep′ is the photon’s energy after the collision,
and Eb is the electron’s binding energy. As mentioned above, Eb is small compared
to the other energies and can usually be neglected. The mass attenuation coefficient
associated with Compton scattering depends on the photon energy and can be approx-
imated as(
µ
ρ
)
compton
∝ Z
A
E−np , (2.5)
for photon energies between 0.2 MeV and 10 MeV, where Z is the atomic number, A is
the atomic mass number and n varies between 0.5 and 1 (Krieger, 2012; Metcalfe et al.,
1997).
2.3.2 Coherent Scattering
Coherent scattering occurs when a photon is merely deflected in the vicinity of an
atomic electron that can be considered bound. This form of scattering can be observed
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when the electron’s energy of ionization Eion is much larger than the energy of the
photon. The incident photon causes the electron to oscillate and the oscillating electron
emits a photon at the same wavelength as the original photon, but it may be deflected
by a small angle. As mentioned above, coherent scattering is negligible at energies
above 100 keV and thus not of particular relevance to radiation therapy (Metcalfe et al.,
1997).
2.3.3 Photoelectric Effect
A photoelectric interaction occurs if a photon strikes a bound atomic electron (i.e.
Eion  Ep) and transfers all of its energy to the electron. If the electron is an inner
shell electron, it will leave the shell and an outer shell electron may take its place re-
leasing a new photon with a characteristic energy equal to the energy difference of
the shells. The ejected electron obtains the kinetic energy Ekin which is equal to the
original photon energy minus the electron’s binding energy
Ekin = Ep − Eb (2.6)
For energies around and below 0.1 MeV, the mass attenuation coefficient can be calcu-
lated as (Khan, 2010)(
µ
ρ
)
photo
∝ Z3E−3p , (2.7)
for high atomic numbers and(
µ
ρ
)
photo
∝ Z3.5E−3p , (2.8)
for low Z materials (Khan, 2010; Krieger, 2012).
2.3.4 Pair Production
If a photon interacts with the electromagnetic field of a nucleus it can be absorbed
and produce an electron positron pair. In order for pair production to occur, the en-
ergy of the photon Ep must be larger than twice the rest mass energy of electrons and
positrons, i.e. 2m0c2 = 1.022 MeV. After the interaction, the electron and positron share
the energy difference between the photon energy Ep and the 2m0c2 necessary for their
generation, though not necessarily equally. On average, each of their kinetic energy is
equal to half the difference between the photon energy Ep and twice the electron rest
mass energy
Ēkin,e± =
Ep − 2moc2
2
, (2.9)
where Ēkin,e± denotes the average acquired kinetic energy of the electron or positron.
The positron will interact with an electron in the body and produce two 0.511 MeV
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Ep
Ek
Ep′
Figure 2.4: Schematic of photoelectric absorption.
e−
Ep
e+
e−
0.511 MeV
0.511 MeV
Figure 2.5: Schematic of pair production.
photons via electron-positron annihilation. The mass attenuation coefficient can be
calculated as(
µ
ρ
)
pair
∝ Z
2
A
logEp, (2.10)
until it saturates at high photon energies Ep.
2.4 Energy Deposition and Absorbed Dose
As described above the photons interact with tissue via Compton scattering, photo-
electric interactions and pair production processes and transfer all or part of their en-
ergy to electrons that gain kinetic energy. The kinetic energy that is transferred by the
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photons to charged particles is termed kinetic energy released per unit mass (KERMA)
K =
dEtr
dm
= Ψ
(
µtr
ρ
)
, (2.11)
where dEtr is the average energy transferred to charged particles as kinetic energy per
interaction, and µtr is the energy transfer coefficient, which is defined as the fraction
of photon energy transferred to kinetic energy of charged particles per unit thickness
(Khan, 2010). The electrons then further transfer their kinetic energy via ionization
and excitation. However, a small portion of the electrons’ kinetic energy may radiate
away as bremsstrahlung and does not contribute to local energy deposition. Thus the
KERMA comprises two terms - collision KERMA (Kcol) and radiative KERMA (Krad).
Kcol = Ψ
µab
ρ
=
dEtr
dm
(1− g), (2.12)
Krad =
dEtr
dm
g, (2.13)
where g is the fraction of energy that is radiated away as bremsstrahlung, and µab is
the absorption coefficient, which is defined as
µab = µtr(1− g). (2.14)
Absorbed dose is defined as the (mean) energy deposited per unit mass
D =
dĒ
dm
, (2.15)
and is responsible for damaging tumor cells and other tissues. Although the colli-
sion KERMA is close to absorbed dose for lower photon energy and both share the
same unit, they differ for higher photon energies. This is because higher energy elec-
trons may travel large distances before they finally deposit their kinetic energies in the
medium. As most electrons are scattered in the direction of the beam, dose is displaced
downstream of KERMA. Figure 2.6 shows a schematic of absorbed dose and KERMA
as functions of depth and demonstrates this effect. Figure 2.7 shows a measured per-
centage depth dose curve in water for 6 MV. When secondary electron equilibrium is
present, that is the number and energy distribution of electrons entering and exiting
the volume is equal, the collision KERMA and absorbed dose can be considered to
coincide.
Furthermore, contamination electrons can contribute to dose in the tissue. Contam-
ination electrons are generated via scattering interactions of the X-ray photon beam
with the components of the treatment head of the LINAC and can contribute to dose
on the patient surface.
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Figure 2.6: Absorbed dose and kerma. Figure by Khan et al. (Khan, 2010).
Figure 2.7: Percentage depth dose curve in water for 6 MV photons measured along
the central axis of a 10 cm × 10 cm field.
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Treatment Planning
The treatment planning process begins with the so-called simulation, during which
an initial computed tomography (CT) scan referred to as the planning CT is acquired,
and skin marks or tattoos are placed in order to reproduce the position of the patient
during the course of treatment. The planning CT is then used to delineate the region of
interest (ROI) including the tumor and organs at risk (OARs). While the CT is usually
the primary imaging modality for tumor delineation, other imaging modalities such as
magnetic resonance imaging (MRI) and positron emission tomography (PET) may be
used to aid in the process. Margins are often added to the tumor contour to account for
various types of uncertainties. A physician specifies the treatment dose and constraints
to OAR, and medical physicists or dosimetrists design a treatment plan including the
beam energy, beam angles, field shapes and weighting factors. The planning CT is
also used to calculate the resulting dose distribution. Finally, the treatment plan is
evaluated and approved by a medical physicist and a physician, often dosimetrically
verified in a phantom, and delivered to the patient. The full treatment dose is usually
not given in a single course, but instead delivered in several small doses called frac-
tions (see subsection 3.4.2 for rationale). Thus, a typical treatment lasts up to several
weeks with daily or nearly daily treatment fractions.
3.1 Target Definitions
After a planning CT scan and potentially additional images such as an MRI and a PET
scan are acquired, the treatment target ROIs gross tumor volume (GTV), clinical tar-
get volume (CTV) and planning target volume (PTV) are defined and contoured on
the planning CT scan. The concepts of these targets are defined by the International
Commission on Radiation Units and Measurement (ICRU) (International Commission
on Radiation Units and Measurements, 1999). The GTV contains the visible, macro-
scopic tumor area to be treated based on the planning CT and information obtained
from other imaging modalities. However, microscopic disease may extend beyond the
visible tumor mass in the planning scan. Since it is imperative for curative radiother-
apy to kill all tumor cells, a margin is introduced, which creates a larger target volume
that accounts for microscopic disease, referred to as the CTV. The PTV accounts for
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geometrical uncertainties and is created by adding an additional margin to the CTV.
The uncertainties can be systematic or random, and they can occur within one fraction
(intra fractional) or between fractions (inter fractional). How far the CTV to PTV mar-
gins extend, depends on the treatment technique and clinical protocols used. Figure
3.1 demonstrates the GTV, CTV and PTV concepts. For tumors in areas where the po-
sition of the GTV and CTV is likely to change during a treatment fraction, an internal
target volume (ITV) enclosing several CTVs may be utilized (Berthelsen, 2007). For
example, ITVs are frequently employed for lung stereotactic body radiation therapy
(SBRT), where several GTV contours for different breathing phases are delineated.
OARs are also contoured on the planning CT in order to be able to evaluate dose
to normal tissues later in the treatment planning process. Since the PTV extends into
normal tissues, a trade-off must be found between sufficient dose coverage of the PTV
and limiting the dose to OAR. Thus, what constitutes optimal margins is subject to
continuing research and the magnitude of the margins varies between institutions,
treatment modality, anatomical location, and treatment protocols.
GTV
CTV
PTV
‘
Figure 3.1: Concept of gross tumor volume (GTV), clinical target volume (CTV) and
planning target volume (PTV).
3.2 Treatment Techniques
3.2.1 Early Beginnings and Two Dimensional Radiation Therapy
The first cancer patients were treated with radiation therapy in 1896 (e.g. (Despeignes,
1896)), very shortly after Röntgen had discovered X-rays in 1895. Until the 1930s, ra-
diation therapy was delivered using Coolidge tubes or radium tubes. These devices
were limited to 50-200 kV and only superficial tumors could be treated, as deliver-
ing dose to tumors seated more deeply would have exceeded the tolerance doses for
the skin and subcutaneous tissues (see chapter 2, Figure 2.7). In the late 1940s, cobalt
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60 units, which generated 1.17 MeV and 1.33 MeV photon beams and made it pos-
sible to spare cutaneous tissues, were first used. Starting in the 1950s, the invention
of medical linear accelerators (LINACs), which could generate energies of 6-20 MV,
paved the way for treatment of deeply seated tumors with doses of up to 60-70 Gy
(Thariat et al., 2012). At that time, the only images available for treatment planning
were two dimensional (2D) bony radiographic images, which is why radiation ther-
apy at that time is referred to as two dimensional radiation therapy (2D-RT). The fields
used were rectangular in shape which led to exposure of large parts of OAR to radia-
tion and thereby limiting the maximum dose to the tumor compared to contemporary
treatment techniques. Custom made blocks that tailored the field shapes to the tumor
were also available, but were impractical as they were difficult to produce and handle.
Since the 1970s, radiation therapy has undergone significant improvements, such as
the development of three dimensional conformal radiation therapy (3D-CRT), inten-
sity modulated radiation therapy (IMRT) and image guided radiation therapy (IGRT),
which will be discussed in the following.
3.2.2 Three Dimensional Conformal Radiation Therapy
The invention of CT in 1971 (Hounsfield, 1980; Beckmann, 2006) paved the way for
a major improvement in radiation therapy. Beginning in the 1980s, the radiographic
images used in 2D-RT were gradually replaced by CT images which allowed treat-
ment planning in three dimensions and thus much more accurate delivery of dose.
Radiation therapy was also further improved by the invention of multi leaf collima-
tors (MLCs) (see section 2.1) in the 1990s, which made it possible to utilize fields that
are much more tailored to the tumor anatomy and the surrounding tissue on a patient
individual basis. Thus, 3D-CRT made further tumor dose escalation possible. While
computer based treatment planning systems (TPSs) were available before 3D-CRT,
the use of CT scans made the use of computers imperative. The availability of three
dimensional (3D) information also necessitated the use of dose volume histograms
(DVHs) which are now one of the main measures for evaluating treatment plans (see
section 3.4.1 for more information on DVHs). In 3D-CRT, planning is performed for-
ward, which means that a plan is designed by manually specifying the beam direc-
tions, beam weights and field shapes. The resulting dose is then calculated and evalu-
ated and the fields are adjusted if necessary.
3.2.3 Intensity Modulated Radiation Therapy
Conventional 3D-CRT uses relatively uniform beam fluences throughout one field.
IMRT is a newer technique that has been clinically used since the late 1990s and early
2000s and employs non-uniform fluence to deliver radiation. This is achieved by vary-
ing the leaf positions of the MLCs during the beam delivery, thereby creating many
segments of different shapes for each beam. IMRT can be delivered as ’step-and-shoot’
IMRT, where the beam is turned off when switching from one segment to the next, or
dynamically as ’sliding window’ IMRT where the collimator leaves move continu-
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ously while the beam is on. More recently, techniques, such as volumetric modulated
arc therapy (VMAT), that vary the leaf positions while the beam direction and dose
rate are changing, have been introduced as well (Khan, 2010; Teoh et al., 2011). IMRT
allows for sparing OARs by better conformation of dose around the tumor and by de-
livering concave isodoses. A dose escalation study for prostate cancer by Zelefsky et
al. shows that patients treated with IMRT had significantly less gastro intestinal (GI)
toxicities than patients treated with 3D-CRT, despite the fact that IMRT patients were
treated to higher doses (Zelefsky et al., 2008). In contrast to 3D-CRT, the fluence and
beam segments of IMRT plans are computer optimized by specifying treatment plan
objectives and constraints, rather than specifying the field shapes manually. Objec-
tives are the functions to be optimized. For example one objective of an IMRT plan
may be to maximize the minimum dose in the tumor to ensure all tumor cells will
be destroyed. Another example may be to minimize the mean dose to an OAR. Con-
straints, on the other hand, are conditions that must be satisfied by an optimal treat-
ment plan. For instance, constraining the maximal acceptable mean dose to an OAR
could avoid creating harmful treatment plans. The use of constraints in IMRT plan-
ning varies among institutions. While some institutions employ both objectives and
constraints, others rely only on the use of objectives to optimize treatment plans.
3.2.4 Image Guided Radiation Therapy
IGRT refers to the use of imaging before or during treatment (Jaffray, 2012; Verellen
et al., 2008) and therefore is not a treatment method in itself, but is combined with
other treatment modalities such as 3D-CRT and IMRT. The main goal of IGRT is to en-
sure the accurate delivery of dose to the tumor while also attempting to spare normal
tissues from unnecessary irradiation (although IGRT requires additional imaging that
may include ionizing radiation). During the course of treatment, imaging is used to
reduce setup errors. IGRT images are most commonly acquired using electronic por-
tal imaging devices (EPIDs), cone beam computed tomographies (CBCTs) and ultra
sound (US), and are compared to the planning CT in order to locate the tumor and
positioning the patient more accurately. This allows for the reduction of CTV to PTV
margins and thus sparing critical structures (Guckenberger, 2011).
IGRT can be used for both online and offline correction strategies. For offline cor-
rection, data is gathered during several initial treatment sessions and used to deter-
mine the best position adjustments during the remaining course of treatment. Thus,
offline corrections reduce systematic errors but cannot account for random errors. In
online IGRT, the patient and tumor position is determined immediately before treat-
ment, or even monitored during one treatment fraction, and adjustments to the posi-
tion or beam are made immediately if necessary. Online strategies can reduce random
errors, however their implementation into clinical use is difficult and requires more
resources and effort (e.g. both hardware and software are needed to register the im-
ages). Furthermore, the additional daily imaging using CBCT raises concerns about
damaging effects from imaging dose.
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Historic Image Guidance, Portal Images, and Electronic Portal Imaging Devices
In the early beginnings of radiation therapy, image guidance was not generally avail-
able, although sporadic ideas may have existed (Verellen et al., 2008). The low energies
used in radiation therapy at that time did not allow enough radiation to pass through
the patient to obtain images of sufficient quality. Accurate positioning was mainly
ensured by immobilization of the patient and skin marks. After medical LINACs gen-
erating MV photon beams were invented, portal images (PIs) became an option for im-
age guidance. They were obtained by placing radiographic films beneath the patient
and recording 2D projections from the LINAC beam. Based on bony anatomy, this pro-
jection could then be compared to simulation X-ray images, or digitally reconstructed
radiograph (DRR), which are 2D projections reconstructed from the planning CT scan.
However, since the Compton effect is the dominant interaction of photons in the MV
range with tissues, noise from scattering limited the quality of the images. PIs were
still of comparatively poor quality, showing low soft tissue contrast. Furthermore, the
films had to be developed and could not be used immediately. Since the 1980s, EPIDs,
have gradually replaced PIs. EPIDs used more sensitive digital detectors rather than
film and acquired digital images which made immediate setup corrections, automatic
image analyses, and faster data sharing possible. EPIDs yield slight improvements
over PI in terms of contrast and overall image quality, but are still subject to the limita-
tions of using the MV beam for imaging and are restricted to two dimensions. Despite
those shortcomings, they are valuable imaging tools and continue to be used in clinical
practice today.
Cone Beam Computed Tomography
With the advent of CBCTs in 2000, it has also become possible to reconstruct 3D images
and use them for image guidance. CBCTs consist of an X-ray source and a 2D digital
detector. In contrast to EPIDs, a source mounted to the gantry at a 90◦ angle from the
beam serves as an X-ray source in most CBCT devices, rather than the LINAC beam
itself. The detector is placed 180◦ from the source. The X-ray source and detector can
be rotated in order to obtain several 2D projections that are used to reconstruct a 3D
image. The majority of CBCT devices use a kV source, although MV CBCTs that use
the MV treatment source are also available (Srinivasan et al., 2014). CBCTs were first
used in dentistry and were later introduced and optimized for radiation therapy by
Jaffray (Jaffray and Siewerdsen, 2000). CBCTs have several advantages: The images
have a high spatial resolution and due to the use of kV radiation rather than MV, the
images have less scattering artefacts. Since the images are 3D, they can be compared to
the planning CT directly, without generating DRRs. This makes it possible to correct
the patient’s position with 6 degrees of freedom (3 translational, 3 rotational) if the
couch is capable of performing these movements (Dhabaan et al., 2012).
Other imaging modalities, such as US, CTs on rails, MRIs, stereoscopic X-rays, and
fluoroscopy, are also available or under investigation for IGRT, but are less frequently
used clinically.
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3.2.5 Adaptive Radiation Therapy
The information obtained via IGRT cannot only be used to shift the patient position,
but also in order to make changes to the treatment plan during the course of treatment,
a concept called adaptive radiation therapy (ART) (Yan et al., 1997). Adaptations to
the treatment plan may be necessary for a number of reasons including anatomical
changes (tumor shrinkage and deformation, weight loss) or functional changes (e.g.
altered radiosensitivity because of hypoxia). ART can be done offline, online or po-
tentially even real-time. During offline ART, images obtained during the first few
treatment fractions are used to estimate tumor changes (movement and anatomical
deformation) in order to create a new treatment plan which is adapted to altered con-
tours and margins. This new plan is then used for the remaining treatment fractions
(Yan et al., 2000). The treatment plan may be adapted once, multiple times or not at
all, depending on the individual patient and the available clinical resources. In on-
line ART, the treatment plan is adapted based on information acquired immediately
before a treatment fraction is being delivered. It is conceivable that treatment plans
could even be adapted continuously during one treatment fraction (real-time ART).
The implementation of ART is resource and labor intensive (images have to be regis-
tered to the planning CT, adapted plans have to be designed and evaluated, etc.). Yet,
ART has evolved rapidly in the past 15 years and is increasingly utilized in the clinic
(Li, 2011).
3.3 Dose Calculation
The dose distribution delivered to the patient cannot be measured directly, but must
be calculated prior to treatment. There are several different methods of calculating
this dose. Kernel based convolution/superposition methods rely on models, whereas
Monte Carlo (MC) simulations and Boltzmann transport equation (BTE) solvers cal-
culate dose using few approximations. There are three major categories of dose calcu-
lation algorithms used by contemporary treatment planning systems: (1) pencil beam
(PB) algorithms, (2) collapsed cone (CC) algorithms, and (3) MC simulations (Khan,
2010; Ahnesjö and Aspradakis, 1999). BTE solvers are less commonly used clinically,
but have recently been implemented into commercial TPS (Eclipse, Acuros XB, Varian
Medical Systems, Palo Alto, CA, USA). In the following, these algorithms will be de-
scribed briefly. However, it is to be noted that many variations and implementations
of the algorithms exist and there may be considerable variation between implementa-
tions.
3.3.1 Kernel Based Superposition/Convolution Methods
All superposition/convolution algorithms use a similar approach for calculating dose.
The first step is to generate an accurate beam model, which requires modelling the
beam properties and energy spectrum based on machine characteristics. The beam
22
3.3. Dose Calculation
model can then be used to calculate the primary energy fluence Ψ(r) before any tissue-
beam interactions have occurred. The primary energy fluence and the mass attenua-
tion coefficient (µ
ρ
) are used to determine total energy released per unit mass (TERMA)
using equation
T (r) = Ψ(r)
(
µ
ρ
)
. (3.1)
As described in chapter 2, the dose at any given position r consists of the primary dose
and scattered dose from secondary particles such as Compton scattered electrons and
photons from points r′ and differs from collision kinetic energy released per unit mass
(KERMA) and TERMA. Thus, in order to calculate dose, the TERMA is convolved with
a dose spread function, also referred to as a point kernel
D(r) =
∫
T (r′)A(r − r′)d3r′. (3.2)
The dose spread function A gives the dose distribution that results from a given pri-
mary interaction point r′. It is typically pre-calculated using MC simulations (Mackie
et al., 1988). The convolution integral gives the dose at point r resulting from all pri-
mary interaction points r′ that contribute to the dose in r. The dose kernel A is gener-
ally calculated for water and needs to be corrected for electron density heterogeneities
in the patient. Thus the kernels are scaled to the radiologic path length ρr−r′(r − r′)
from the primary interaction site r′ to r. The radiologic path length is defined as the
distance corrected for electron density relative to water (Khan, 2010). Scaling results
in the following equation for the dose:
D(r) =
∫
T (ρrr
′)A(ρr−r′(r − r′))d3r′, (3.3)
where ρrr′ is the radiologic path length from the source to r′ (Khan, 2010). Full su-
perposition/convolution calculations can be computationally expensive, because for a
complete calculation, the dose contributions from all voxels to all other voxels would
have to be considered. Childress et al. estimate 1007 calculations are needed for a
volume of 30x30x30 cm3 and 3 mm resolution (Childress et al., 2012). Thus various
approximations, such as pencil beam algorithms and collapsed cone algorithms, have
been proposed and implemented in order to reduce calculation times.
Pencil Beam
PB algorithms (Mohan et al., 1986) assume that the beam consists of many infinitesi-
mally small pencil shaped beams along the primary beam direction. Dose is calculated
as a superposition of the corresponding dose deposition kernels (referred to as pencil
beam kernels) and TERMA. The pencil beam kernels can be calculated using MC sim-
ulations for different energies, or they can be determined by integrating pre-calculated
point kernels along the pencil beams. An example of a pencil beam kernel is shown in
Figure (3.2). PB calculations are generally fast, especially in homogeneous media.
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Figure 3.2: Dose deposition point kernel (left), pencil beam kernel (right). Figure by
Ahnesjo and Aspradakis (Ahnesjö and Aspradakis, 1999).
Tissue inhomogeneities are considered by scaling the PB kernels based on equiva-
lent path length, which is calculated from the total electron density between the point
of incidence of the pencil beam and the voxel in which dose is deposited along the
direction of the beam. The PB kernels are thus shortened for high densities and elon-
gated for low electron densities. However, these corrections are only applied in the
direction of the beam, whereas laterally all matter is assumed to be water. Thus, the
PB lacks accuracy in inhomogeneous tissues, despite the density corrections, and sec-
ondary interactions other than in the beam direction are completely omitted.
Collapsed Cone
CC algorithms rely on the angular discretization of kernels into cones (Ahnesjö, 1989;
Ahnesjö and Aspradakis, 1999; Childress et al., 2012). They calculate the dose result-
ing from a primary interaction site r′ in voxels within cones that have an apex at the
primary interaction site voxel r′. The entire dose in the cone is deposited only in the
voxels along the central axis of the cone. Since the other voxels within the cone receive
dose from neighboring cones, and each voxel may be included in several cones, this
does not lead to large deviations. The accuracy of CC algorithms and also the calcula-
tion time depend on the number of cones used. Tissue inhomogeneities are accounted
for by rectilinear rescaling of the dose deposition kernels.
In contrast to the PB algorithms, CC algorithms model lateral scattering and backscat-
ter to some extent and yield improved dose calculations, especially in inhomogeneous
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Figure 3.3: Dose deposition kernel with rectilinear rescaling (solid) and calculated
with Monte Carlo (dotted). Figure by Woo and Cunningham (Woo et al., 1990).
media. However, lateral scatter is still simplified, as CC algorithms neglect multiple
scattering processes. Figure 3.3 shows a rectilinearly rescaled dose deposition kernel,
compared to MC calculations.
3.3.2 Direct Methods
Monte Carlo Simulations
A MC simulation (Andreo, 1991; Ahnesjö and Aspradakis, 1999) is a stochastic method
that is used for many parts of the dose calculation process such as for calculating the
kernels used in the superposition/convolution methods. However, MC simulations
can also be used to calculate dose directly without the use of kernels. MC algorithms
simulate the trajectories and interactions of photons and contamination electrons from
the LINAC head. Which interaction occurs for a given particle and where the interac-
tion occurs is determined based on random numbers that are compared to interaction
probabilities. The algorithms follow a particle and all secondary particles created by
that particle until they are either absorbed, leave the area of interest, or cannot interact
any more. This process is repeated for a large number of particles in order to obtain
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statistically representative results. Typically, between 107 and 108 photons need to be
simulated for clinical purposes.
MC simulations can be categorized into full MC simulations and fast MC simula-
tions. Full MC simulations include simulating interactions in the LINAC head. They
are computationally expensive, but if the parameters are well defined, full MC dose
calculation algorithms are extremely accurate. Fast MC simulations use a pre-calcu-
lated virtual source model instead of simulating processes in the source and treatment
head for each simulation. Thus, fast MC calculations are much faster and can be used
for routine clinical purposes. MC simulation have been shown to agree well with mea-
surements and are considered the gold standard of dose calculation algorithms.
Boltzmann Transport Equation
In contrast to the stochastic MC based dose calculation algorithms, BTE solvers are
deterministic approaches to dose calculation. The BTE describes macroscopic proper-
ties of the interaction of photons and electrons with matter. Dose can be calculated by
solving coupled systems of linear BTEs numerically. The accuracy of BTE algorithm
depends on the variable discretizations. If the spatial and energy discretization is in-
finitesimally small, the solution of the BTE system converges to same solution as a MC
simulation with infinitely many particles. For a review of BTE based dose calculation
see (Kan et al., 2013).
3.4 Treatment Plan Evaluation
3.4.1 Three Dimensional Dose Reduction
Depending on the resolution a typical CT scan may contain approximately 2.5 × 105
voxels per slice. In clinical practice it is not feasible to explicitly consider the dose
in each of these voxels for assessment of the quality of a treatment plan. Thus, the
3D dose distribution within ROIs is often reduced to DVHs and the plan quality is
evaluated based on simplified measures derived from those histograms (see Chapter
4). Differential dose volume histograms (dDVHs) are calculated by binning voxels
with similar dose and recording their combined volume or frequency. Since there is
considerable variation in organ sizes and other structures among patients, the DVH is
often displayed in terms of relative volume rather than absolute volume:
dDVH(Di) = vi, (3.4)
where vi is the relative volume of all voxels within dose bin Di. In the clinic, however,
knowing what volume percentage of a structure receives a certain dose or higher is
often more relevant than knowing the dDVH. Thus, the DVH is usually displayed as
a cumulative dose volume histogram (cDVH):
cDVH(Di) = 1−
∑
i|D>Di
vi. (3.5)
Figure 3.4 shows a sample dDVH and its corresponding cDVH for the lungs.
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(a) Differential DVH (b) Cumulative DVH
Figure 3.4: Differential and cumulative dose volume histograms of the lung.
3.4.2 Biological Effect of Physical Dose and Fractionation
Radiosensitivity, Cell Kill and Surviving Fraction
As described in the beginning of chapter 2, cells are destroyed by ionizing radiation
damaging the cells’ deoxyribonucleic acid (DNA). The exact relationship between the
magnitude of dose received by tissues and the fraction of cells that survive continues
to be under investigation. Several models describing the relationship have been pro-
posed over time but the linear quadratic (LQ) model (Fowler, 1989; Hall and Giaccia,
2006) is the most established model and is currently being used clinically. Based on the
LQ model, DNA can be damaged by a single interaction or two double strand breaks
in the same DNA strand. While a single double strand break can usually be repaired
by a cell, two double strand breaks can cause the cell to die. Lethal damage caused by
single interactions, such as mutations of vital genes, are assumed to be linearly related
to the dose D via αD, whereas lethal damage caused by two double strand breaks
show a quadratic relationship with dose βD2. The coefficients α and β refer to as the
linear and the quadratic coefficient, respectively. The lethal events are assumed to be
Poisson distributed with αD + βD2 which yields a surviving fraction SF
SF(D) = e−αD−βD
2
. (3.6)
The coefficients α and β are constants for a single cell type that need to be determined
by experiment, but they vary in between different cell types. Already in the early be-
ginnings of radiation therapy it was discovered that tissues differ in how severely they
are affected by the same dose of ionizing radiation (Bergonié and Tribondeau, 1906), a
characteristic referred to as radiosensitivity. The radiosensitivity of a cell depends on
how rapidly that cell type divides, what stage of the cell cycle the cell is currently in,
and many other factors. It is not a static property, but can be altered by external fac-
tors. For example, Read showed that oxygen is an important radio-sensitizer (Read,
1952). Thus, the radiosensitivity of cells and tissues can change during the course of
treatment, for instance if a tumor becomes hypoxic.
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Fractionation
In 1927, the effects of fractionation on tumor versus normal tissue were first discovered
(Regaud and Ferroux, 1927). Nowadays, radiation is usually delivered in several frac-
tions, rather than a single dose, as this has proven beneficial for sparing normal tissues
and inflicting increased damage on tumor cells (Withers, 1975). A sufficient amount
of time in between fractions allows normal tissue cells to repair in between treatments
while tumor cells exhibit only little ability to efficiently repair. Another benefit of frac-
tionation is the reassortment of tumor cells to the stage of the cell cycle in which they
are more radiosensitive (Hall and Giaccia, 2006). Furthermore, fractionated radiother-
apy allows hypoxic areas at the center of the tumor to become reoxygenated and thus
increases cell kill in the tumor in the subsequent fraction. However, prolonged time
between treatments can also counteract the latter effects, because it allows the tumor to
regrow. Therefore, effective radiotherapy needs to optimize the time between adjacent
fractions, depending on the tumor and surrounding tissue type. Standard fractionated
radiation therapy (SFRT) is given in doses of 1.8 Gy to 2 Gy. The surviving fraction for
fractionated treatment, according to the LQ model can be calculated as
SF(d, n) = SF1(d)× SF2(d)× . . . SFn(d)
= en(−αd−βd
2)
6= SF(D),
where d denotes the dose per fraction, n the number of fractions, and D the total dose.
Since cell survival changes with fractionation, the physical dose calculated by the treat-
ment planning system needs to be corrected for fractionation effects in many cases. A
quantity called biologically effective dose (BED) can be used to compare different frac-
tionation schemes:
BEDLQ
(
d, n,
α
β
)
= n
(
d+
d2
α
β
)
, (3.7)
where d is the dose per fraction, n is the number of fractions delivered. Two fraction-
ation schemes produce identical effects, if they produce the same BED. For clinical
purposes the BED is sometimes normalized to 2 Gy per fraction, which is referred to
as normalized total dose (NTD). The NTD is defined as
NTD2,LQ = nd
1 + dαβ
1 + 2α
β
 . (3.8)
The ratio α
β
marks the dose at which the linear component of cell kill equals the quadratic
component (Hall and Giaccia, 2006) and, as mentioned above, is tissue specific. Large
α
β
(> 10 Gy) usually indicate tumor tissue or early effects in normal tissues, while small
α
β
indicate late complications of normal tissue. There are exceptions however, such as
some prostate and breast tumors which have been shown to have α
β
ratios as low as
1.5 Gy and 4 Gy, respectively (Brenner et al., 2002; Zaorsky et al., 2013; Whelan et al.,
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2008). Figure 3.5 demonstrates the effect of fractionation on tumors in contrast to nor-
mal tissues based on the LQ model. While the surviving fraction in normal tissues is
much higher if the total dose is given in fractions, the effect is much less pronounced
in the tumor.
Figure 3.5: Surviving fraction SF after total dose D, given in one fraction of 10 Gy
(dashed line) and 5 fractions of 2 Gy (solid line).
Hypofractionation
As mentioned above, SFRT is very effective for tumors with high α
β
ratios. However, it
is less effective for those tumors with unusually low α
β
ratios (Brenner et al., 2002; Whe-
lan et al., 2008). Thus, hypofractionated radiation therapy (HFRT), that is treatment in
fractions larger than 2 Gy per fraction, has been proposed for breast and prostate tu-
mors, and was studied in clinical trials with successful outcomes for breast cancer (Ray
et al., 2015; Zaorsky et al., 2013). HFRT can reduce the number of fractions to less than
ten fractions, and in some cases a single fraction may be used. Consequently, it re-
duces the overall treatment time, which leads to lower costs of treatment and is more
convenient for the patient.
Due to continuing improvements in normal tissue sparing, HFRT is now also used
to treat tumors with typical α
β
ratios (≥ 10). This type of treatment was made pos-
sible by reducing treatment volumes (due to smaller margins), making it possible to
irradiate less normal tissues. A common form of HFRT is stereotactic body radiation
therapy (SBRT), which is a type of radiation treatment during which large doses per
fraction are delivered to an extracranial treatment volume with high precision. The
dose is commonly delivered in 1-5 fractions between 10 Gy and 20 Gy per fraction.
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SBRT requires a high level of accuracy throughout the treatment planning process in-
cluding stereotactic target localization using IGRT, beams from multiple angles, im-
mobilization of the patient, and accurate dose calculation algorithms. SBRT was first
implemented in order to improve local control of small inoperable lung tumors and
has become standard of care for this type of tumor. SBRT is also used in other tumor
sites, including lung, liver, pelvis and head and neck (Rubio et al., 2013).
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As described in Chapter 1, adequately predicting a patient’s probability of develop-
ing side effects from radiation is vital for improving radiation therapy. One method
of estimating the risks associated with a treatment plan is normal tissue complication
probability (NTCP) modelling. An NTCP model assigns a probability of a certain com-
plication to a summary measure derived from a patient’s dose distribution. For exam-
ple, the probability of a patient experiencing radiation pneumonitis may be modelled
as a function of the mean dose delivered to the lung. It is to be noted that NTCP models
are specific to an endpoint rather than organ specific and several distinct side effects
with distinct dose responses can occur from irradiation of the same tissue. In order
to successfully use NTCP models in the clinic, the model parameters have to be de-
termined by fitting the model to pre-existing data on dose distributions and the tox-
icities that resulted from them. NTCP modelling is performed in the following basic
steps. First, the toxicity data and dose distribution, typically in form of dose volume
histograms (DVHs), are collected for a large patient population. Using large patient
populations is necessary because treatment plans are designed to keep the incidence of
toxicities low. Thus, several hundreds of treatment plans that have been collected over
years may be needed in order to provide a sufficient number of toxicities for NTCP
modelling. After the data is collected, maximum likelihood estimation (MLE) is used
to fit the data to an NTCP model and determine the optimal model parameters for
the population. Once the parameters are determined, the fit of the model to the data
should be verified. Ideally, the model should also be cross verified with another set
of patients, but in practice the availability of data is often limited. Collecting a suffi-
cient amount of patient data is both time consuming and costly. Older treatment plans
may have to be recovered from archives and recalculated with newer treatment plan-
ning systems. Extra time has to be expended on properly evaluating and documenting
toxicities, and toxicity scores of earlier patients may have to be re-scored if the scor-
ing criteria have changed over time. Once the validity of the model is established, a
patient’s DVH can be plugged into the model to determine the patient’s individual
NTCP.
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4.1 Toxicity Scoring
Toxicity scoring constitutes the basis of NTCP modelling. Toxicities, also called ad-
verse events, are typically scored by physicians at several follow-up visits during and
after treatment. However, some protocols rely on patient reported symptoms or a com-
bination of patient and clinician reported symptoms (Gilbert et al., 2015; Olsson et al.,
2015; Christodoulou et al., 2014). The most common methods of grading toxicities is on
a scale that reaches from absence of symptoms to lethal symptoms. Throughout this
thesis, the Common Terminology Criteria for Adverse Events (CTCAE) scoring sys-
tem was used (National Cancer Institute, 2006). Table 4.1 shows the general definition
of the CTCAE grades. Grade 0 generally marks the absence of symptoms, while grade
1 is assigned to mild symptoms that do not need intervention. Toxicities of grade 2 and
higher typically have a considerable impact on a patient’s quality of life. However, not
all grades are available for all adverse events. For example, some types of side effect
cannot lead to death and therefore, grade 5 is not applicable to these toxicities. For the
purpose of NTCP modelling, the toxicities need to be converted to binary values (0 or
1), and thus be pooled into two dichotomous groups (see 4.5). In many studies, grade
0 and grade 1 toxicities are pooled in one group (value 0), whereas toxicities of grade
2 and higher are pooled in the other group (value 1). The rational for this way of pool-
ing is twofold: For one, grade 1 toxicities are mild and usually not clinically relevant.
Furthermore, the distinction between grade 1 and grade 0 is often not reliable. Grade
1 toxicities may be asymptomatic except for microscopic evidence of tissue damage,
and thus cannot be easily verified in each patient without expensive testing that is
not clinically indicated. More details on toxicity scoring, especially bias arising from
toxicity scoring, can be found in Section 5.2.1.
Grade Description
1 Mild adverse event
2 Moderate adverse event
3 Severe adverse event
4 Life-threatening or disabling adverse event
5 Death related to adverse event
Table 4.1: Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
(National Cancer Institute, 2006).
4.2 Dose Volume Histogram Reduction
Although the DVH (see Chapter 3) constitutes a large reduction of the vast informa-
tion contained in the three dimensional dose distribution, it still contains too much
information for clinical use. When comparing two given DVHs it may not be clear
which one is preferable over the other in terms of the probability of side effects. In
fact, which one is preferable will depend on the specific endpoint associated with the
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organ under consideration. Several methods have been proposed for a further reduc-
tion of the DVH to a single metric that can rank DVHs according to their probability of
causing toxicities. Those metrics can be divided into two broad categories - (1) single
point DVH reduction methods and (2) equivalent uniform dose (EUD) measures.
4.2.1 Single Point Dose Volume Histogram Reduction
Single point DVH reduction methods are summary measures that are points of the
DVH curve. Prominently used examples are cutoff dose volumes such as VDc , the
volume that receives a dose equal or higher than the cutoff dose Dc (Söhn, Yan, Liang,
Meldolesi, Vargas and Alber, 2007):
VDc = VcDVH(Dc) =
∑
i|Di≥Dc
vi, (4.1)
where Di is a dosebin of the DVH, vi is the relative volume that received dose Di,
and VcDVH(Dc) is the volume of the cumulative DVH at Dc (see Equation 3.5). Other
examples are the maximum dose (Dmax) or minimum dose (Dmin) received by a struc-
ture. These metrics are beneficial in clinical practice as they allow an easy evaluation
of DVHs and side effect probabilities without further calculations. However, they may
omit too much relevant information contained in the DVH in some cases.
4.2.2 Equivalent Uniform Dose Metrics
The second category of DVH reduction metrics is based on the concept of EUD and
comprises predictors which take the entire dose distribution or DVH into account. The
EUD is defined as the homogeneous dose irradiated to the entire organ, that would
have the same effect on the organ, in terms of a certain endpoint, as a given heteroge-
neous dose distribution. If the local effect density of a given dose D is equal to f(D),
the total effect F of a heterogeneous dose distribution {Dk, vk}k=1,...,K in a structure
with K voxels
F ({Dk, vk}k=1,...,K) =
∑
k
vkf(Dk),with
∑
k
vk = 1, (4.2)
where Dk is the local dose in voxel k and vk is the relative volume of voxel k in the
dose distribution. This effect is required to be equivalent to the effect of a uniform
dose D = EUD
F ({Dk, vk}k=1,...,K) = f(EUD), (4.3)
and the EUD is therefore
EUD = f−1 (F ({Dk, vk}k=1,...,K)) = f−1
(∑
k
vkf(Dk)
)
. (4.4)
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The EUD can also be defined in terms of a DVH with dosebinsDi and relative volumes
vi:
EUD = f−1 (F (DVH)) = f−1
(∑
i
vif(Di)
)
. (4.5)
The true effect (density) is usually not known and could involve complex biologi-
cal processes. However, several concepts have been proposed to model EUD. The
most commonly used model for the effect density f for organs at risk (Niemierko,
1999) is the power law as used for the generalized equivalent uniform dose (gEUD)
fgEUD(D) = D
a. The corresponding EUD of a DVH is then simply the p-norm with
p = a.
gEUD(DVH) =
(∑
i
viD
a
i
) 1
a
. (4.6)
The gEUD is sometimes referred to as the effective dose (Deff). Other models for the lo-
cal effect of dose and EUD have been proposed as well, including mechanistic models,
e.g. (Alber and Belka, 2006).
4.3 Volume Effect and Tissue Architecture
Although the gEUD concept is mainly algebraic and not derived from a biological
background, its parameter a is sometimes interpreted as an indicator of the functional
nature of the tissue. This parameter a is referred to as the volume-effect parameter,
because it determines the importance of dose and volume on the effect on the tissue.
Essentially, it determines whether a low dose to a large volume (a small) is more dam-
aging than a high dose to a small volume (a large) or vice versa.
The gEUD converges to the maximum dose Dmax for large a, and is equal to the
mean dose for a = 1
lim
a→∞
gEUD (DVH, a) = Dmax(DVH),
lim
a→1
gEUD (DVH, a) = Dmean(DVH).
A graph demonstrating DVHs representing gEUD for a lung DVH for several values
of a is shown in Figure 4.1. In this context reference is often made to parallel or serial
tissue architecture of organs. Organs that do not experience toxicity until a certain vol-
ume threshold of tissue damage is reached (such as liver and lung) are referred to as
parallel organs. Organs that can tolerate small doses to large volumes, but cause toxic-
ity as soon as a small volume receives a large dose are termed serial organs (e.g. spinal
cord, rectum). However, dividing entire organs into serial and parallel without con-
sidering the specific endpoint can be misleading. For example, bleeding is generally
a serial complication, while radiation pneumonitis is considered a parallel complica-
tion. Both parallel and serial complications may occur in the same organ. Although
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Figure 4.1: Generalized equivalent uniform dose (gEUD) for several values of the vol-
ume effect parameter a
characterization of tissues as serial or parallel can be useful, one must not forget that
in reality the biological processes that determine tissue organization can be immensely
complex.
4.4 Normal Tissue Complication Probability Models
When creating a treatment plan for a patient, one is interested in determining the prob-
ability NTCPi that a patient with a DVHi will experience a complication, or toxicity
yi. This probability is generally not known, and as pointed out above the biologi-
cal processes behind it can be very complex. However, NTCP models can be used
in order to provide an approximation for that probability. Numerous NTCP models
have been proposed, ranging from simple models for homogeneous partial irradia-
tion (Lyman, 1985) to complex ones incorporating biological mechanisms (Alber and
Belka, 2006; Burman et al., 1991; Lyman, 1985). Marks et al. (Marks et al., 2010) estab-
lished guidelines for heterogeneous three dimensional conformal radiation therapy
(3D-CRT) within the framework of the Quantitative Analyses of Normal Tissue Ef-
fects in the Clinic (QUANTEC) reports and presented the most commonly used NTCP
models.
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4.4.1 Cutoff Dose Logistic Regression Model
The cutoff dose logistic regression (CDLR) model is a logistic regression of the volume
VDc receiving a cutoff dose Dc or higher (Equation 4.1)
NTCP(Dc) =
1
1 + exp (−β0 − β1VDc)
. (4.7)
The volume causing 50 % complication is the ratio of the logistic regression coeffi-
cients, VDc,50% = −β0β1 . The logistic regression model can also be used with other met-
rics such as Dmean and EUD, for example.
4.4.2 Lyman Equivalent Uniform Dose Model
The Lyman EUD model was introduced by Lyman, and extended by Kutcher and
Burman (Lyman, 1985; Kutcher and Burman, 1989). It is also called the Lyman Kutcher
Burman (LKB) model. The model assumes that NTCP is a sigmoidal function of the
EUD:
NTCP(EUD) =
1√
2π
∫ t
−∞
exp
(
−x2
2
)
dx, with (4.8)
t =
EUD− EUD50
mEUD50
. (4.9)
EUD50 denotes the EUD causing a 50% chance of experiencing a complication and m
is a parameter that is inversely related to the slope of the NTCP curve at EUD50. This
model is sometimes written more conveniently as an error function
NTCP(EUD) =
1
2
(
1 + erf
(
EUD− EUD50√
2mEUD50
))
. (4.10)
4.5 Model Fitting
4.5.1 Maximum Likelihood Estimation
In order to determine the parameters of the NTCP models in Equation 4.7 or 4.9, the
model must be optimized for a sample dataset. This is done using MLE or sometimes
using other methods such as least square estimation. However, MLE should be the
preferred method, because it is more generally applicable (Burnham and Anderson,
2004) and does not rely on binning of the binary toxicity data (Cox, 1989). In MLE
the likelihood L of the model is maximized for a measurement of the set of toxicities
{yi}i=1,...,n, for n patients, where yi is the toxicity caused by DVHi. The yi are dichoto-
mous, that is they can have two values, either yi = 0 or yi = 1. If the NTCP model
parameters denoted by θwere known, the probability p of measuring a set of toxicities
{yi} caused by {DVHi} for n patients (i = 1, . . . , n) could be calculated as
p(y1, . . . , yn,DVH1, . . . ,DVHn |θ) =
n∏
i=1
(NTCPi(DVHi |θ))yi (1− NTCPi(DVHi |θ))1−yi ,
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(4.11)
since the values yi are independent. That is, the probability is a function of the data
given the parameters θ. However, the model parameters θ are not known and need
to be estimated by fitting known data to the NTCP model. Thus, rather than a func-
tion of the data given the parameters θ, a function of the parameters θ given the data
yi(DVHi) needs to be optimized. This function is called the likelihood L:
L(θ|{yi,DVHi}) =
n∏
i=1
L(θ|yi,DVHi) (4.12)
=
n∏
i=1
(NTCPi(θ|DVHi))yi(1− NTCPi(θ|DVHi))1−yi . (4.13)
To determine the optimal model parameters θopt, the likelihood function is maximized
with respect to θ giving the MLE estimator:
θopt = arg max
θ
L(θ). (4.14)
Since the logarithm preserves the position of the maximum, lnL(θ) is maximized
rather than L(θ) to simplify the calculation to a sum rather than a product:
lnL(θ) = ln
n∏
i=1
Li(θ) =
n∑
i=1
lnLi(θ). (4.15)
The expression lnL(θ) is referred to as the log likelihood (LL).
4.5.2 Implementation
While the MLE estimator can be calculated analytically for simple problems in a closed
expression, this is not possible for complex problems like NTCP modelling. All MLE
estimators in this thesis were therefore calculated numerically using Mathematica
(Wolfram Research Inc., Version 9.0-10.3, Champaign, IL) and software developed by
the author based on C++.
4.6 Comparing Models
The likelihood value or log likelihood value of a model has no absolute value and is
not comparable between datasets. However, within a given dataset, the value of the
likelihood function at the optimal parameters can be used to compare different models
if one model is a sub-model of the other (that is, one or more parameters are fixed).
The likelihood ratio test (Pawitan, 2001) can be used in that case to determine if there
is a significant improvement of the more advanced model (the full model) over the
simpler version of the model (the reduced model). The likelihood ratio is computed as
LR = 2 (lnLfull − lnLreduced) , (4.16)
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where Lfull is the maximum likelihood of the full model, whereas Lreduced is the max-
imum likelihood of the reduced model, in which at least one parameter is fixed. The
likelihood ratio LR is then compared to the 100(1− α)th percentile of a chi-square
distribution with df degrees of freedom χ21−α(df), where df is the difference in model
parameters between the full model and the reduced model. If the value of LR is larger
than χ21−α(df), there is significant improvement of the full model over the reduced
model at a significance level of 100(1− α) %.
Adding parameters to the model will also increase its likelihood of over-fitting the
data and fitting noise. Akaike et al. published a criterion known as Akaike information
criterion (AIC) to correct the log likelihood values for the number of parameters of the
model (Akaike, 1974; Burnham, 2004). It is calculated as
AIC(LL, k) = 2k − 2 LL, (4.17)
where LL is the log likelihood lnL(θopt) of the model and k is the number of model
parameters. A lower AIC value indicates the superior model. If the sample size n is
low, the AIC can be further corrected, using the corrected Akaike information criterion
(AICc). The AICc is dependent on the model, but can be estimated by
AICc(LL, k, n) = AIC +
2k(k + 1)
n− k − 1
. (4.18)
Just like the value of LL, neither the AIC, nor the AICc can determine the absolute
quality of the NTCP model.
4.7 Goodness of Fit
Goodness of fit of a particular model can be determined using a Hosmer-Lemeshow
goodness of fit test (Collett, 2003; Hosmer and Lemesbow, 1980). A Hosmer-Lemeshow
statistics χ2HL is calculated from the data grouped into g groups:
χ2HL =
g∑
i=1
(oi −miπi)2
miπi(1− πi)
, (4.19)
wheremi is the total number of observations, oi the observed number of successes, and
πi the average expected success probability in the i-th group. The goodness of fit p-
value is obtained by comparing χ2HL to a χ
2 distribution with g−2 degrees of freedom.
Obtaining a low p-value (p < 0.05) signifies that the null-hypothesis, that the data
stems from the same distribution as the theoretical model, can be rejected. The model
is considered to yield an acceptable fit to the data if p > 0.05 (95% confidence) (Collett,
2003).
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4.8 Standard Errors and Confidence Intervals
4.8.1 Variance Covariance Matrix
The standard errors and confidence interval (CI) of the maximum likelihood estimate
θopt can be calculated via the Hessian matrix H(θ) of the log likelihood function (Paw-
itan, 2001)
H(θ) =
∂2 lnL(θ)
∂θi∂θj
, (4.20)
assuming that the maximum likelihood estimator is normally distributed. From the
Hessian matrix, the variance-covariance matrix var(θ) can be calculated as the inverse
of the negative of the Hessian matrix
var(θ) = (−H(θ))−1 . (4.21)
Standard errors of the parameters θopt are the square roots of diagonal elements of the
variance covariance matrix evaluated at θopt. That is, the standard error estimate ŝe of
a parameter θopt,i can be determined as
ŝe(θopt,i) =
√
vari,i(θopt) =
√
vari,i(θ)|θ=θopt (4.22)
and 95% CI for each parameter can be calculated as
θopt,i ± 1.96ŝe(θopt,i). (4.23)
4.8.2 Profile Likelihood Method
Another way to estimate CIs for θopt, without assuming normality of the maximum
likelihood estimator, is using the profile likelihood method (Pawitan, 2001; Böhning
et al., 2008). If the parameter of interest is denoted by θi and the remaining parameters
are θj , then the profile likelihood function is defined as
Lprof(θi) = max
θj
L(θi,θj). (4.24)
To calculate 100(1− α)% CI, one has to find the interval of θi for which
lnLprof(θi) > ln (L(θopt))−
χ21−α(1)
2
, (4.25)
where χ21−α(1) is the 100(1− α)th percentile of a chi-square distribution with 1 degree
of freedom.
4.8.3 Bootstrapping
Bootstrapping is another method for determining better standard errors of the max-
imum likelihood estimator, especially when the sample size is small (Efron and Tib-
shirani, 1998). Bootstrapping estimates the standard error by repeated analysis of re-
samples of the original dataset. Let {DVHi, yi}, i = 1, . . . , n be the set of patient DVHs
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with the respective scored toxicities, and θopt the ML estimates for the parameters θ. In
order to obtain the standard error of θopt, a new set of n random samples {DVHj, yj},
j = 1, . . . , n is drawn from {DVHi, yi} with replacement, which means the new DVHs
are always drawn from the entire original set of DVHs, even if a particular DVH has
already been drawn before. Since the new set of DVHs was drawn with replacement,
some of the DVHs from the original set may occur twice in the new set while others
may not be part of the new set at all. The MLE analysis is performed on that new set
{DVHj, yj} in exactly the same way as on the original dataset {DVHi, yi}, i = 1, . . . , n,
and a new estimate for θ is recorded. This type of resampling is repeated K times,
generating K sets of DVHs and their respective toxicities with n patients in each set.
For each of these K sets a new estimate θopt,k, k = 1, . . . , K is calculated and stored.
The estimate of the standard error ŝe(θopt) of θopt and CI of θopt is then calculated as
the standard deviation σ of the K values θopt,k:
ŝe(θopt) = σ ({θopt,k}k=1,...,K) . (4.26)
Alternatively, CI can be estimated by calculating the 5th and 95th percentile of {θopt,k}k=1,...,K
(Burnham and Anderson, 2004).
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Chapter 5
Influence of Treatment
Technique
Publication: Comparison and Limitations of DVH based NTCP Models Derived from
3D-CRT and IMRT Data for Prediction of Gastrointestinal Toxicities in Prostate Cancer
Patients Using Matched Pair Analysis 1
5.1 Introduction
In this chapter, the applicability of normal tissue complication probability (NTCP)
models derived from a patient population treated with a specific treatment technique
to a second population treated with a different technique was investigated. Specifi-
cally, it was determined whether models derived from a population treated with three
dimensional conformal radiation therapy (3D-CRT) can be applied to intensity mod-
ulated radiation therapy (IMRT) patients and vice versa. It has been shown that cur-
rent NTCP models can work well if applied to the population and treatment-technique
they were derived from (Michalski et al., 2010). It is unclear, however, whether they are
reliable predictors of toxicity when applied to a different treatment-modality (Michal-
ski et al., 2010), especially since the observed incidence of toxicities can differ vastly
between treatment-techniques. The issue is of major relevance, as most NTCP model
parameters are derived from 3D-CRT data (Michalski et al., 2010), but are frequently
used to estimate complications for intensity-modulated radiotherapy (Luxton et al.,
2004). While a single patient’s NTCP will depend on the dose distribution received,
ideally the NTCP model parameters for a specific organ/tissue should not depend on
the actual dose-distribution delivered to that organ, regardless of treatment-technique.
However, commonly used NTCP models potentially lack the complexity to resemble
the underlying biological processes, or the model parameter estimates might be bi-
1Reprinted (adapted) with permission from “Comparison and Limitations of DVH-Based NTCP Models
Derived From 3D-CRT and IMRT Data for Prediction of Gastrointestinal Toxicities in Prostate Cancer Patients
by Using Propensity Score Matched Pair Analysis” by Troeller, A., Yan, D., Marina, O., Schulze, D., Alber,
M., Parodi, K., Belka, C., Söhn, M.; Int. J. Radiat. Oncol. 91, 435–443. doi:10.1016/j.ijrobp.2014.09.046
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ased by a cohort with little variability in dose levels (Hardcastle et al., 2010). Further-
more, commonly used NTCP models are based on dose volume histogram (DVH)s
which leave out spatial information. Bias can also arise from toxicity scoring, as nei-
ther the patient nor the physician performing the follow-up (FU) can be blinded to
the technique. Also the evolution of improved image guidance contemporaneously
with IMRT may play a role. The topic is further complicated by differences in patient
characteristics inherent to the populations. In the following, a selection of possible
factors influencing toxicity models are generally discussed, followed by an overview
of matched pair analysis for comparing treatment groups. Then, a study investigat-
ing the topic is presented. In this study, NTCP model parameters for gastro intestinal
(GI) toxicities were derived for a large, matched population of prostate cancer patients
treated at a single institution with 3D-CRT or IMRT, in order to investigate discrep-
ancies in toxicities between treatment-techniques. Best-fit parameters were calculated
for all patients (3D-CRT+IMRT) as well as the 3D-CRT and IMRT sub-groups sepa-
rately, and it was determined how well a model fits the data it was derived from and
how well it fit the data it was not derived from. The impact of differences between the
3D-CRT and IMRT patient characteristics, image-guidance, bias of toxicities and other
possible causes of differences in NTCP modelling results are discussed.
5.2 Factors Influencing Toxicity Modelling
5.2.1 Toxicity Scoring Bias
As pointed out in part I of this thesis, proper scoring of toxicities is crucial for NTCP
modelling. However, although scoring systems such as the Common Terminology Cri-
teria for Adverse Events (CTCAE) attempt to objectively evaluate toxicities, the scores
are recorded by physicians based on their interpretation of patient-reported signs and
symptoms, and thus may contain a certain bias. How side-effects are perceived may
be influenced by the patient’s and physician’s knowledge of the treatment-technique.
Such bias, unfortunately, cannot easily be excluded.
Furthermore, the follow-up time can play an important role in NTCP modelling.
For example, if the follow-up time is not sufficiently long, patients who might have
later experienced side effects of higher grades may have accidentally been categorized
as grade 0. This can potentially change the NTCP model parameters and needs to be
considered when comparing groups.
5.2.2 Errors of Planned Versus Delivered Dose
The dose calculated for a treatment plan differs from the actual dose delivered to the
patient due to uncertainties such as motion and positioning. The magnitude of this er-
ror of the planned dose used to model NTCP may differ for treatment techniques. For
example, both treatment techniques differ in dose gradients which may influence the
impact of motion errors and positioning errors on the truly delivered dose in different
ways. Furthermore, because of different technological advances such as image guided
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radiation therapy (IGRT) contemporaneously with newer treatment techniques, the
magnitude of the difference between planned and delivered dose may vary between
treatment techniques. A more detailed discussion of these effects especially in refer-
ence to the study presented below, can be found in Section 5.6.
5.2.3 Confounding Patient Characteristics
When NTCP modelling is compared or applied to different patient populations, such
as patient populations receiving different kinds of treatment, there may be confound-
ing factors that need to be considered. For example, a history of smoking can in-
fluence how lung tissue reacts to radiation (Alsadius et al., 2011; Solanki and Liauw,
2013). Consequently, if two populations differ significantly in how many of the pa-
tients smoke, NTCP models derived from such populations may differ as well. Many
other endpoint dependent confounding factors have been identified for various tis-
sues. For the GI toxicities investigated in this study, advanced age, diabetes and ab-
dominal surgery prior to radiation therapy, hemorrhoids, androgen deprivation ther-
apy (ADT), larger rectal volume, anticoagulants, and possibly smoking have been
shown to influence the incidence of toxicities (Budäus et al., 2012; Valdagni et al., 2012).
5.3 Matched Pair Analysis
Ideally, two groups to be compared should be randomized to avoid bias from con-
founding variables. Unfortunately, this is not always possible for ethical or practical
reasons. It would not be ethical, for example, to randomly expose patients to a cer-
tain type of treatment, when it is well known that another treatment is superior in
treating their specific condition. In order to study and compare models for different
groups, one therefore has to adjust for selection bias. This can be done using matched
pair analysis to match pairs of patients from both populations with similar patient
characteristics (Guo and Fraser, 2015; Rosenbaum and Rubin, 1983). If there are only
few confounding variables that are categorical, it is possible to match patients exactly.
That is, for each patient from one group, a patient with the exact same values of con-
founding variable is selected from the other group. However, in practice confounding
variables are often continuous, or there is a multitude of confounding variables, and
exact matching is not possible. In these cases, propensity score based matched pair
analysis can be used.
Propensity score matching is performed in three steps:
1. Propensity Score Calculation: A measure for similarity in confounding vari-
ables, the propensity score, is calculated for each patient in the two groups g1
and g2.
2. Matching: Patients from group g2 are matched to group g1 based on the propen-
sity score.
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3. Post Matching Analysis: The datasets are analyzed regarding remaining differ-
ences in confounding variables and the match may be repeated with different
parameters if significant differences remain between the matched groups.
5.3.1 Propensity Score
The propensity score P is defined as the conditional probability of a patient i being
assigned to group 1 (i.e. Gi = 1, for example the group of patients with GI toxicities
of grade ≥ 2) given the value of the confounding variables xi (Rosenbaum and Rubin,
1983):
P (xi) = p(Gi = 1|Xi = xi). (5.1)
The propensity score for each patient can be estimated by fitting the toxicity data of the
entire patient population to a logistic regression model of the confounding variables
xi:
P (xi) =
1
1 + exp(−xiβi)
, (5.2)
where βi are the regression coefficients. The βi are determined by fitting the binary
data (i.e. Gi = 1 if the patient was assigned to group 1 with toxicity grade ≥ 2, and
Gi = 0 if the patient was assigned to group 2, with toxicity grade< 2) to the propensity
score model using maximum likelihood estimation (MLE) (see Section 4.5). Once the
logistic model parameters are determined, the propensity score for each patient can
be calculated in both groups and be used as a similarity measure. Proper selection of
which covariates should be included is important but non-trivial. Guo and Fraser note
that although several methods have been proposed, no standard method of selecting
covariates currently exists (Guo and Fraser, 2015).
5.3.2 Matching
After the propensity score has been calculated for each patient in groups g1 (e.g. 3D-
CRT) and g2 (e.g. IMRT), pairs of patients from group g1 and group g2 that had sim-
ilar probabilities of being in group G1 or G2 based on the confounding variables are
matched based on their propensity score. Several matching methods/algorithms have
been proposed, such as greedy matching, optimal matching, and fine matching which
are discussed below. The matching process involves a trade-off between a minimal
difference between the populations on the one hand and loss of patients on the other
hand. The dataset may be reduced due to several factors: Some patients may not have
a decent match in the other group, and similarly some control patients may never be
used as a match.
Greedy Matching
The defining characteristic of greedy matching is that once a match has been selected
for a specific patient, he or she will not be rematched. The matching patient will be
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removed from the pool of possible matches for the remaining patients to be matched.
Thus, greedy matching does not always select the best possible match as a match that
was removed from the pool g2 may be a better fit for another patient from g1. Further-
more, greedy matching needs a relatively large overlap of the two groups. Advan-
tages of greedy matching is that it fullfills the assumptions of multivariate analysis
techniques (Guo and Fraser, 2015) and the ability to perform incomplete matches in
which not every patient from group g1 receives a match. There are several submethods
of greedy matching, such as nearest neighbor matching, caliper matching or a combi-
nation of the two.
Optimal Matching
In contrast to greedy matching, optimal matching is a non-linear process which dif-
fers from greedy matching in that matches are constantly re-evaluated in favor of a
possible closer match. A distance measure based on propensity scores is minimized
over all possible pairwise matches. Optimal matching allows for variable matching in
which each patient from the treatment group may be matched to a variable number of
patients from the control group. Unlike greedy matching, the optimal match needs to
be complete (Guo and Fraser, 2015).
Fine Balance Matching
Fine balance matching balances a variable rather than finding an optimal match for
each patient. That is in fine balance matching, pairs of patients may be matched even
if their propensity score is not similar as long as the matching variables are balanced
overall (Rosenbaum, 2010).
5.3.3 Post Matching Analysis
The major component of post matching analysis is comparing the groups again and
evaluate whether significant differences between the groups remain or have resolved.
In the former case, matching could be repeated with more tightly restricted parameters
at the expense of a smaller final dataset. If the matched sample shows no significant
difference in the confounding variables the dataset can be used for modelling. How-
ever, in cases where the match is performed for further processing and analysis of the
groups, a variety of post matching analysis methods exists and can be used.
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5.4 Modelling Normal Tissue Complication Probability
for Three Dimensional Conformal Radiation Ther-
apy and Intensity Modulated Radiation Therapy Data
5.4.1 Patient Data
For this study, 1,115 patients treated for prostate cancer (1999-2010) were selected from
a prospective prostate cancer database. Patients with a FU of at least 2 years were
investigated for the occurrence of GI side-effects after radiotherapy. Of these patients,
457 were treated with conventional 3D-CRT, while 658 received IMRT. The endpoints
considered in this study were chronic GI toxicities grade≥ 2 as defined by the CTCAE
v. 3.0. These include rectal bleeding, rectal pain, diarrhea, proctitis, fistulae and anal
fissures.
5.4.2 Treatment Planning with Three Dimensional Conformal Radi-
ation Therapy and Intensity Modulated Radiation Therapy
All patients were treated under an adaptive radiation therapy (ART) protocol (Yan
et al., 2000). The treatment plan is divided into an initial and an adapted treatment-
plan. On the planning computed tomography (CT) acquired for each patient the initial
planning target volume (PTV) was constructed by adding a 1 cm margin to the clinical
target volume (CTV). The CTV consisted of either prostate or prostate and seminal-
vesicles. A four-field-box was created and treated for the first five fractions for all pa-
tients. During the first week of treatment, daily portal images (PIs) and four CT scans
were acquired. From these images the specific set-up error and mobility of each patient
was estimated in order to construct a non-uniform, so called confidence-limited PTV
with adapted margins. For the 3D-CRT patients an adapted-plan consisting of a new
four-field-box was constructed, whereas for the IMRT patients an adapted IMRT plan
was created, typically incorporating 5-7 beams. The adapted plans were used for treat-
ment of all remaining fractions. Portal imaging was repeated once a week thereafter,
to adjust patient setup. Starting in 2007, all PIs were replaced by cone beam computed
tomography (CBCT), which affected 29 % of the IMRT patients. PI were matched to the
digitally reconstructed radiograph (DRR) of the original planning CT via bony match,
and and CBCTs were matched to the planning CT using bony anatomy. Prescribed
doses ranged from 70.2 Gy to 82.8 Gy with a median of 75.6 Gy, delivered in 1.8 Gy
fractions. The organs at risk (OARs) were outlined on the initial CT scan only. The rec-
tum was contoured from the lower of the anal verge or ischial tuberosities to the higher
of the sacroiliac joints or recto-sigmoid junction (Vargas et al., 2005). A rectal wall con-
tour was generated, by constructing a 3-4 mm ring inside the outer rectum contour.
The bladder was contoured as a solid organ. The major dose-volume constraints were
V75.6Gy ≤ 30% and V82Gy ≤ 5% for rectal wall, Dmax ≤ 85Gy and V75.6Gy ≤ 50% for
bladder.
Composite dose-distributions, of the combined initial plan and the adapted plan,
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and composite DVHs were calculated on the planning CT using Pinnacle’s hetero-
geneity corrected adaptive-convolve algorithm (Philips Pinnacle 3, Versions 6.2-9.0,
Philips Healthcare, Andover, MA). The same algorithm was used for all patients; the
plans were re-calculated and exported retrospectively using Pinnacle scripts. Con-
tours were created in Pinnacle. All CT scans were taken with 3 mm slice-thickness.
DVHs were exported for rectal wall in dose-bins of 0.1 Gy.
5.4.3 Follow-Up
The FU protocol recommended examinations every three months for the first two
years after treatment, every six months until five years after treatment and yearly
thereafter. The FU data was acquired prospectively by the treating physicians and
documented using CTCAE v.2.0 and CTCAE v.3.0. It was reviewed and amended to
the CTCAE v. 3.0 by a single physician in 2011 - 2012 to ensure consistency of the
toxicity scoring.
5.4.4 Application of Matched Pair Analysis
In order to account for most of the major possible differences in patient characteris-
tics between the 3D-CRT and IMRT groups, a matched-pair analysis was performed
on the datasets. Patients were investigated regarding several suspected confounding
variables: age at diagnosis, diabetes mellitus (DM) and pelvic surgery prior to ra-
diation therapy (RT), use of androgen deprivation therapy (ADT) prior to or during
RT, rectal wall volume, PTV volume and National Comprehensive Cancer Network
(NCCN) risk-groups. Data on smoking, hemorrhoids, abdominal surgery and hyper-
tension was not available for most patients and was not included. The 3D-CRT and
IMRT groups were matched based on the characteristics with low p-values (p < 0.1).
Those characteristics included age, rectal wall volume, DM prior to treatment, and
risk group. Greedy matching using a hybrid of exact matching (for the risk group)
and propensity score matching (all other patient characteristics) was used to match the
groups (see 5.3). Matching was implemented in R 2.15.1 (R-project.org, Vienna, Aus-
tria) using the ”Matching” package (Sekhon, 2008). The patient characteristics before
and after matching are presented in Table 5.1. After matching, the groups comprised
275 and 550 patients with 79 (28.7 %) and 43 (7.8 %) toxicities, respectively, and did not
show significant difference in rectal wall volume, risk-group, age and diabetes (Table
5.1). ADT showed a significant difference after matching that was of small magnitude
(26 %/19 %). ADT has been associated primarily with abdominal pain and diarrhea
(Kumar et al., 2005). The former was not part of this study, the latter occurred in less
than 2% and 1% of all 3D-CRT and IMRT patients, respectively, and thus the matching
was not repeated in favor of a larger number of patients.
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Charac- 3D-CRT IMRT p-value 3D-CRT IMRT p-value
teristic matched matched matched
Number of 457 658 275 550
patients
Time of 1999-2006 2001-2010 1999-2006 2001-2010
treatment
Median RxD, 75.6 Gy 75.6 Gy < 0.01 75.6 Gy 75.6 Gy <0.001
range 70.2-79.2 Gy 70.2-82.8 Gy 70.2-79.2 Gy 70.2-82.8 Gy
Median FU, 8.9 yrs 4.6 yrs <0.001 8.8 yrs 4.7 yrs < 0.001
range 2.0-12.5 yrs 2.0-9.0 yrs 2.0-12.5 yrs 2.0-9.0 yrs
GI-toxicity, 127 (27.8 %) 48 (7.3 %) <0.001 79 (28.7 %) 43 (7.8 %) <0.001
grade ≥ 2
Age at Dx, 72 yrs 70 yrs < 0.001 71 yrs 71 yrs 0.46
range 51-87 yrs 45-86 yrs 51-87 yrs 45-86 yrs
Diabetes 67 109/571 0.06 41/275 77/477 0.73
(14.7%) (19.1%) (15%) (16 %)
Past pelvic 161/455 134/352 0.48 89/274 120/305 0.1
surgery (35.4%) (38.1 %) (32%) (39%)
Pre/During 106 131 0.21 72 102 0.02
Tx ADT (23.2 %) (19.9 %) (26%) (19%)
Risk-Group†: <0.001 1
low 230 (50.3%) 228 (34.7%) 105 210
intermediate 168 (36.8%) 313 (47.6%) 129 258
high 59 (12.9%) 117 (17.8%) 41 82
Rectal wall 31.3 cm3 24.7 cm3 <0.001 25.7 cm3 25.5 cm3 0.7
volume ± 12.1 cm3 ± 7.5 cm3 ± 7.6 cm3 ± 6.9
PTV volume 140.2 cm3 140.3 cm3 0.9 136.0 cm3 142.0 cm3 0.12
± 52.7 cm3 ± 50.4 cm3 ± 52.4 cm3 ± 51.3 cm3
† Risk-groups are defined as low if PSA < 10, Gleason score ≤ 6 and T-stage ≤ T2a,
intermediate if PSA < 20, Gleason ≤ 7 and T-stage ≤ T2b and high otherwise.
Table 5.1: Patient characteristics and follow-up (FU) time for three dimensional con-
formal radiation therapy (3D-CRT) and intensity modulated radiation therapy (IMRT),
and p-values for difference between the two groups before and after matching.
5.4.5 Normal Tissue Complication Probability Models and Statistics
For this study, the Lyman equivalent uniform dose (EUD) model (Equation 4.9) and
the cutoff dose logistic regression (CDLR) model (Equation 4.7) described in chapter 4
were used to model NTCP for matched 3D-CRT and IMRT patients and the combined
group. The endpoint of the study were GI toxicities grade≥ 2. The models were based
on DVHs of the rectal wall contour. Additionally, NTCP for GI toxicities was modelled
using full rectum DVHs. Furthermore, optimal NTCP model parameters were calcu-
lated for a subgroup of all IMRT patients that were treated before CBCTs were used
(pre-CBCT).
The model parameters and standard-errors were determined by means of MLE
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Lyman EUD
model
a EUD50 m LL
3D-CRT 4.76 (0.50, 15.64) 69.0 Gy (60.1Gy, 77.2Gy) 0.182(0.076, 0.639) -157.4
IMRT 12.27 (1.50,∞) 87.9 Gy (77.3Gy, 160Gy) 0.159 (0.071, 0.542) -148.9
3D-CRT+IMRT 11.50 (4.01, 21.6) 75.5 Gy (71.7Gy, 79.1Gy) 0.089 (0.081, 0.186) -324.6
QUANTEC 11.11 (7.14, 25.00) 76.9 Gy (73.7Gy, 80.1Gy) 0.13 (0.10, 0.17) -
CDLR model Dc β0 β1 LL
3D-CRT 53.9 Gy (44.1Gy, 73.8Gy) -2.54 (-3.49, -1.64) 0.037 (0.018, 0.057) -157.6
IMRT 77.2 Gy (44.3Gy, 78.6Gy) -2.89 (-3.38, -2.44) 0.049 (0.012, 0.085) -147.9
3D-CRT+IMRT 38.8 Gy (24.9Gy, 46.1Gy) -4.19 (-4.85, -3.62) 0.039 (0.030, 0.047) -325.6
Table 5.2: Optimal normal tissue complication probability (NTCP) model parameters
for the matched groups and their 95 % confidence intervals for the Lyman-EUD-model
and the cutoff dose logistic regression (CDLR) model of three dimensional conformal
radiation therapy (3D-CRT), intensity modulated radiation therpay (IMRT), and 3D-
CRT+IMRT data for chronic gastrointestinal (GI) toxicities grade ≤ 2. Optimal param-
eters determined by QUANTEC (Michalski et al., 2010) are shown for comparison.
(Collett, 2003; Cox, 1989; Jackson et al., 1995), using rectal wall DVHs and their cor-
responding dichotomous toxicity data. The confidence intervals (CIs) for the model
parameters were calculated using profile likelihoods. Goodness of fit of a particu-
lar model was determined using a Hosmer-Lemeshow goodness of fit test (Collett,
2003; Hosmer and Lemesbow, 1980). MLE and goodness of fit were performed using
Mathematica (Wolfram Research Inc., Version 9.0, Champaign, IL) and an in-house
developed software (C++).
5.5 Modelling Results
The mean DVHs, a typical dose distribution, and rectal wall DVHs of all patients are
shown in Figure 5.1. The 3D-CRT and IMRT 2 DVHs contained significantly different
volumes in each dose-bin, except for 5-6 Gy, and 83 Gy (Mann-Whitney, 1 Gy bins).
5.5.1 Normal Tissue Complication Probability Model Parameters
Rectal Wall
The model parameters for the Lyman EUD and the CDLR model for GI toxicities using
the rectal wall are summarized in Table 5.2. According to the goodness of fit criteria,
all models were satisfactory fits to the data from which they were derived (p > 0.05).
When comparing models to the data they were not derived from, they yielded un-
satisfactory fits (p < 0.001). NTCP curves derived from the 3D-CRT+IMRT dataset
or the conformal data alone overestimated the NTCP for IMRT patients (Figure 5.2).
2All further reference to 3D-CRT/IMRT will allude to the matched groups.
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In the same manner, curves derived from IMRT data or the combined dataset under-
estimated NTCP for 3D-CRT patients. Additionally, it was evaluated how well the
data of each group fit the Quantitative Analyses of Normal Tissue Effects in the Clinic
(QUANTEC) recommended Lyman EUD NTCP model parameters (Michalski et al.,
2010). The QUANTEC model fit none of the datasets well. The p-values for 6 bins
containing approximately the same total number of patients are shown in Table 5.3,
but other groupings (3, 10, 20) showed similar statistical significance. For the CDLR
model, the cutoff dose Dc yielding the best log likelihood is shown in Table 5.2. Sig-
nificant log likelihood values could be obtained for a range of cutoff doses around
those optimal values (Figure 5.3). The exact position of the optimal Dc varied within
that range. The average difference in volume over all dose bins between the 3D-CRT
and the IMRT DVHs was 5 % (0-17 %). The difference in mean EUD calculated for all
3D-CRT and IMRT DVHs for any a-value in the range of 6 - 20 was < 2 Gy.
Full Rectum
The optimal NTCP model parameters for NTCP modelling using the full rectum con-
tours are shown in Table 5.4. The goodness of fit p-value shows that the model fits the
data well (Table 5.5).
Pre-CBCT IMRT Patients
Additionally, the results for NTCP modelling using only the rectal wall DVHs of pre-
CBCT IMRT patients are shown in Table 5.6 (optimal model parameters) and Table 5.5
(goodness of fit values). The model fits the data well, but does not fit the 3D-CRT data.
5.6 Discussion
NTCP was modelled with respect to GI toxicities for patients treated with 3D-CRT
or IMRT and the estimated model parameters were compared. Matched-pair analy-
sis was performed on the data in order to select sub-groups with comparable patient
characteristics. Overall the difference between planned IMRT and 3D-CRT DVHs was
relatively small. However, both before and after matching, the raw toxicities showed
sizeable and significant (p < 0.001) differences between the 3D-CRT (27.8 % / 28.7 %)
and the IMRT group (7.3 % / 7.8 %), which cannot be explained by those differences
in dose alone. This creates the paradox situation that IMRT, conceived to reduce toxic-
ities by sparing normal tissues from high doses, is successful in the former, but not by
achieving the latter. Consequently, the purely dose-based NTCP modelling parame-
ters derived from the 3D-CRT data do not describe NTCP for IMRT patients and other
reasons for the discrepancies in toxicity need to be considered. In the following, other
possible sources of bias between the groups, as causes of the nearly 4-fold decrease in
IMRT toxicities, are discussed.
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Figure 5.1: Left: (a) All three dimensional conformal (3D-CRT) and (b) intensity mod-
ulated radiation therapy (IMRT) dose volume histograms (DVHs), with patients expe-
riencing gastrointestinal toxicities grade ≥ 2 marked red. Right: Typical 3D-CRT (c)
and IMRT (d) dose-distribution. The red, green, blue, orange, light-red lines are the
81.3 Gy, 77.4 Gy,63.7 Gy, 51.2 Gy, 38.7 Gy iso-doses, respectively. Bottom: Mean DVH
and standard deviation of all patients (solid/filled space), and patients with toxicities
(dashed).
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Figure 5.2: Normal tissue complication probability (NTCP) curves and data for the
Lyman EUD model (a–d) and the cutoff dose logistic regression (CDLR) model (e–h).
The blue, orange, and grey lines are the NTCP curves derived from 3D-CRT, IMRT,
and 3D-CRT+IMRT, respectively. The squares, circles, and triangles are the binned
3D-CRT, IMRT, and 3D-CRT+IMRT data, respectively.
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Figure 5.3: Optimal log-likelihood (LL) of the cutoff dose logistic regression (CDLR)
model in dependence on the cutoff dose for (a) three dimensional conformal radiation
therapy (3D-CRT) data, (b) intensity modulated radiation therapy (IMRT) data, and
(c) 3D-CRT+IMRT data (steps of 1 Gy). The red line indicates the 95 % significance
level.
3D-CRT Lyman-EUD Model pHL† CRT cutoff-dose model pHL†
3D-CRT 0.75 3D-CRT 0.53
IMRT <0.001 IMRT < 0.001
3D-CRT+IMRT < 0.001 3D-CRT+IMRT < 0.001
IMRT Lyman-EUD model IMRT cutoff-dose model
3D-CRT < 0.001 3D-CRT < 0.001
IMRT 0.72 IMRT 0.1
3D-CRT+IMRT < 0.001 3D-CRT+IMRT < 0.001
3D-CRT+IMRT Lyman EUD
model
3D-CRT+IMRT cutoff dose
model
3D-CRT < 0.001 3D-CRT < 0.001
IMRT < 0.001 IMRT <0.001
3D-CRT+IMRT 0.52 3D-CRT+IMRT 0.81
QUANTEC model
3D-CRT <0.01
IMRT <0.01
3D-CRT+IMRT <0.01
†The model is considered to yield an acceptable fit to the data, if the goodness of fit value
p > 0.05, (Collett, 2003).
Table 5.3: Hosmer-Lemeshow goodness of fit p-values for matched data.
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Technique Number of pa-
tients
GI toxicities
grade ≥ 2
a EUD50 (Gy) m
3D-CRT 146 39 [26.7 %] 4.43 (5.37) 68.9 (6.6) 0.175 (0.135)
IMRT 546 43 [7.8 %] 15.33 (25.3) 93.3 (17.9) 0.186 (0.161)
Table 5.4: Optimal normal tissue complication probability (NTCP) parameters for the
Lyman EUD model using full rectum dose volume histograms (DVHs). Standard er-
rors for the parameters are shown in parenthesis
3D-CRT data
(rectum)
pHL IMRT data
(rectum)
pHL IMRT data (rectal
wall, pre-CBCT)
pHL
3D-CRT model
(rectum)
0.11 IMRT model
(rectum)
0.97 IMRT model
(rectal wall, pre-
CBCT)
0.39
3D-CRT model
(rectal wall)
0.11 IMRT model
(rectal wall)
0.80 IMRT model
(rectal wall)
0.38
IMRT model
(rectum)
< 0.001 3D-CRT model
(rectum)
< 0.001 3D-CRT model
(rectal wall)
< 0.001
Table 5.5: Goodness of fit values for the full rectum Lyman EUD model for three di-
mensional conformal radiation therapy (3D-CRT) and intensity modulated radiation
therapy (IMRT) data, and the pre-CBCT IMRT data.
Technique Number of
patients
GI toxicities
grade ≥ 2
a EUD50 (Gy) m
IMRT pre-CBCT 380 35 [9.2 %] 15.1 (15.9) 83.3 (7.3) 0.126 (0.07)
Table 5.6: Optimal Lyman EUD normal tissue complication probability (NTCP) model
parameters for intensity modulated radiation therapy (IMRT) patients treated before
cone beam computed tomography scans (CBCTs) were incorporated into the clinical
routine (pre-CBCT). Standard errors for the parameters are shown in parenthesis.
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5.6.1 Patient Characteristics
Many established patient characteristics related to GI toxicities (Budäus et al., 2012)
were accounted for using matched-pair analysis, or showed no significant difference
between groups prior to matching. However, it is not feasible to account for all possi-
ble sources of bias. Partially this is because not all characteristics are available for every
patient. Furthermore accounting for a larger number of characteristics would reduce
the number of patients/toxicities available for modelling to an insufficient amount.
Nevertheless, it is possible to roughly estimate the influence of various characteris-
tics on toxicities. Among the characteristics that have been found to correlate with GI
toxicities in multivariate studies with dose-volume parameters are pre-RT abdominal
surgery (odds ratio (OR) = 4.7), hemorrhoids (OR = 2.6), ADT (OR = 0.6) and antihy-
pertensive medication (OR = 0.38) (Kumar et al., 2005; Fellin et al., 2013). Assuming a
hypothetical 5 % probability that a patient without abdominal surgery experiences a
toxicity (less than the 7 % incidence in IMRT patients), it can be approximated that for
the observed toxicity rates, 19 % of the IMRT patients in this study would have had
abdominal surgery prior to RT, versus 160 % of the 3D-CRT patients. Although this
is a hypothetical thought experiment and provides only a rough estimate, the unre-
alistic outcome suggests that even the most significant single patient characteristic of
abdominal surgery is unlikely to cause the high discrepancy of toxicities between the
two groups. Even a combination of these patient characteristics could not lead to the
observed difference, as it is unlikely that they all differed to such a marked extent.
5.6.2 Image Guidance
Inaccurate estimation of delivered dose may affect modelling 3D-CRT and IMRT data.
The treatment modalities have different dose-distributions, which could result in a
different error of planned-versus-delivered dose in the two techniques (Schulze et al.,
2009), hindering the development of a common NTCP model. IMRT has gradually re-
placed 3D-CRT for prostate cancer since 2006 at Beaumont Health. During that time,
not only have the treatment-modalities changed, but so has the use, extent and modal-
ity of image guidance. For example, patient positioning and mobility control have im-
proved by replacing PIs with CBCTs. It is conceivable that the decreased proportion
of IMRT patients experiencing toxicity is due to more accurate delivery of dose. How-
ever, both PI as well as CBCTs were registered to the planning CT using bony anatomy
only, not soft tissue. Guckenberger et. al (Guckenberger et al., 2006) have demonstrated
little difference between PI and CBCT in that case. Thus the improvement due to posi-
tioning is likely only slight. Furthermore, with the advent of CBCT it became possible
to compare bladder and rectum volumes to the planning CT before each fraction and
adjust dietary instructions or administer fluid intake, if necessary. However, there
was no official clinical regulation protocol and adjustments were performed only in
extreme cases (< 10 % of cases according to the Beaumont Health imaging special-
ist). In addition, 71 % of IMRT patients in this study were treated before CBCT was
introduced clinically, which also excludes the adjustment of ART margins as a major
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contribution.
Image guidance was further excluded as a source of bias, by the brief analysis that
was performed using the pre-CBCT IMRT patients only. The optimal NTCP parame-
ters (Table 5.6) did not change enough to satisfactorily explain discrepancies between
3D-CRT and IMRT model parameters with changes in image guidance. Goodness of
fit p-values (Table 5.5) show that the NTCP model derived from pre-CBCT IMRT data
is not applicable to 3D-CRT data.
5.6.3 Dose Volume Histograms
Thor et al. investigated the influence of daily organ motion on DVHs and subsequently
on rectal toxicity (Thor et al., 2013). They estimate the worst-case increase in the vol-
ume receiving a given dose between the planned and delivered rectal DVH for a given
patient at approximately 25 %. If all 3D-CRT patients had such a worst-case increase
in volume due to organ motion, whereas none of the IMRT patients did, this would
result in a right-ward shift of the 3D-CRT NTCP curve shown in Figure 5.1(e) of 25 %.
However, the required shift by goodness of fit is 35 %. It is unlikely that such a drastic
systematic error would have been present in one set, but not the other set of patients.
5.6.4 Toxicity Scoring
As mentioned earlier in this chapter (see 5.2.1), it is difficult to exclude toxicity scoring
as a source of bias. Double blind studies in which neither the patient nor the physician
performing the FU know the treatment technique are not only impractical, but also
ethically questionable. The patients in this study were generally seen by different
resident physicians along with the treating physician at each follow-up visit, with an
expected 4 follow-up visits during the first 2 years after RT.
5.6.5 Follow-Up Time
The difference in follow-up time of the groups is also notable. However, Kaplan-Meier
curves for rectal toxicities in prostate patients show that approximately 75-80 % of
complications typically occur within the first 2 years after the end of treatment (Mo-
hammed et al., 2012). Therefore, with a minimum follow-up of 2 years and a median of
4.7 years the FU time of the IMRT group, FU time is not expected to be a major source
of bias between groups.
5.6.6 Limitations of Normal Tissue Complication Probability Mod-
els Used
One factor may be that the DVH leaves out spatial information contained in the three
dimensional (3D) dose distribution that has been suggested to be relevant by some
authors (Acosta et al., 2013; Munbodh et al., 2008; Peeters, Lebesque, Heemsbergen,
van Putten, Slot, Dielwart and Koper, 2006) and has been shown to correlate with late
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complications (Buettner et al., 2009). Therefore, the two DVH based models used in
this study may not be capable of correctly predicting side-effects for both 3D-CRT and
IMRT with similar parameters. Furthermore, the NTCP models used in this study,
especially the CDLR model, may show correlations between specific dose parameters
and toxicities, where there is no actual causal connection (Söhn, Alber and Yan, 2007).
The results of the cutoff dose analysis are influenced by the typical dose distributions
in the patient groups and vary immensely between populations and the combination
of the two populations (Figure 5.3). This suggests that the model in general may not be
adequate in describing true causalities between toxicities and dose. Finally, as patients
are treated within narrow dose-ranges and constraints, the data only allows modelling
of a small section of the entire NTCP curve, inducing increased uncertainty in model
parameters. The few toxicity events further impede NTCP modelling with respect to
uncertainties of parameter estimates, especially in the IMRT population (Table 5.2).
5.6.7 Comparison with Other Studies
Lyman EUD Model
The NTCP parameter values derived for a, EUD50 and m from the 3D-CRT dataset for
the Lyman EUD model using rectal wall were within the range of parameters found
in the literature for rectal toxicities (Marks et al., 2010; Söhn, Yan, Liang, Meldolesi,
Vargas and Alber, 2007; Rancati et al., 2004; Gulliford et al., 2012; Peeters, Hoogeman,
Heemsbergen, Hart, Koper and Lebesque, 2006; Fiorino et al., 2009; Tucker et al., 2004).
The QUANTEC study (Michalski et al., 2010) determined optimal NTCP parame-
ters for GI toxicities via a meta-analysis of several publications. The optimal parame-
ters determined by QUANTEC did not fit the 3D-CRT data in this study, however, the
QUANTEC parameters were within the CIs determined in this study.
Since the QUANTEC report and other literature include studies based on full rec-
tum DVHs, NTCP modelling and analysis in this study was repeated using the entire
rectum for all matched patients who had the full rectum contour available. The opti-
mal NTCP models (Table 5.4) in this case differ little from those obtained with rectal
wall. Thus discrepancies between the QUANTEC parameters and the parameters in
this study are not due to using rectal wall rather than the full rectum. Furthermore, the
models derived for full rectum contours were not cross-applicable between treatment
techniques, which also excludes using rectal wall contours as a source of discrepancies
between 3D-CRT and IMRT (Table 5.5).
Some publications for 3D-CRT modelled NTCP for rectal bleeding only, rather than
all GI toxicities. For comparison, a smaller study for the Lyman EUD model, consid-
ering only rectal bleeding grade ≥ 2, was conducted previously for a sub-population
of this study and resulted in similar conclusions regarding the discrepancy found be-
tween 3D-CRT and IMRT groups (Troeller et al., 2012). Söhn et al. previously modelled
a sub-group of the 3D-CRT population considered in this study with respect to rectal
bleeding (Söhn, Yan, Liang, Meldolesi, Vargas and Alber, 2007) and obtained a = 11.9
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± 3.8, m = 0.108 ± 0.027, and EUD50 = 78.4 ± 2.1. The difference in parameters com-
pared to this study may be due to the smaller patient population with considerably
shorter follow-up of 1 year, and the more specific endpoint.
This study provides model parameters for IMRT patients for the Lyman EUD model.
To the knowledge of the author, no other publications have modelled NTCP for IMRT
patients at this point, likely due to the decreased incidence of toxicities in IMRT pa-
tients and the difficulty obtaining IMRT data. In general, optimal NTCP parameters
vary significantly between studies and populations, and the parameters determined
in this study are not meant to present a recommendation for treatment. On the con-
trary, they show that modelling results depend highly on the exact group of patients
and treatment-modalities used.
CDLR Model
Results for the CDLR model confirm previous publications stating that volumes re-
ceiving doses of 40 Gy or higher are associated with GI toxicities (Söhn, Yan, Liang,
Meldolesi, Vargas and Alber, 2007; Peeters, Hoogeman, Heemsbergen, Hart, Koper
and Lebesque, 2006; Fiorino et al., 2009; Tucker et al., 2004; Jackson et al., 2001). This
study also provides model parameters for IMRT patients for the CDLR model. How-
ever, the best-fit NTCP curves are relatively flat and thus do not carry great predictive
value. For example, 12 % of IMRT patients did not receive doses as high as the optimal
cutoff dose of 77.2 Gy.
5.7 Conclusion
In this large single-institution cohort study, discrepancies between the incidence in GI
toxicities in 3D-CRT versus IMRT patients were investigated, with special emphasis
on NTCP models and their cross-applicability for predicting GI toxicity. The 3D-CRT
derived optimal NTCP parameters fit poorly when applied to IMRT data, and vice
versa. The reasons for the large discrepancies between toxicity incidences remain un-
clear. Matching the populations with respect to the most important clinical parameters
did not resolve the differences that were found. Although, image guidance can fur-
ther affect the extent of GI toxicity, these are unlikely to explain the difference between
the two patient groups. Biases of toxicity scoring cannot be evaluated retrospectively.
Limitations in the class of models explored in this study may result in the observed
lack of fit, but would have to be further investigated and it is possible that other types
of models could resolve the issue. However, NTCP models derived from 3D-CRT data
are used at present in clinical practice. Given the limitations of this exploratory study,
such models would likely not fit IMRT data well. Therefore, such 3D-CRT derived
models should only be applied to IMRT patients with awareness of the issues arising
from extrapolating models to other populations. Fortunately, the 3D-CRT based mod-
els overestimate toxicities for IMRT patients and do not lead to additional toxicities.
They may however prevent dose escalation to increase tumor control, as they predict
more toxicities than may actually be experienced by the patients.
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Influence of Fractionation
6.1 Introduction
As discussed in Chapter 3, Section 3.4.2, radiation therapy is usually delivered in sev-
eral fractions rather than one single dose in order to allow normal tissues to recover
between treatment fractions. Radiobiologically, fractionation is based on the linear
quadratic (LQ) model of cell kill, and the difference in α
β
ratios for tumors (≥ 10 Gy)
and normal tissue (' 3 Gy) that reflect the tumors’ decreased ability to repair com-
pared to healthy tissues. Standard fractionated radiation therapy (SFRT) is given in
fractions of 1.8 Gy to 2 Gy. Various studies have investigated normal tissue complica-
tion probability (NTCP) models for SFRT for a multitude of structures and endpoints.
Hypofractionated radiation therapy (HFRT), that is radiation therapy with more than
2 Gy per fraction, has been introduced into clinical practice more recently. Conse-
quently, less studies on NTCP models for HFRT exist. This chapter investigates the
impact of hypofractionation on NTCP models.
Since dose fractionation impacts the biological effect of physical dose on tissues, al-
tered fractionation schemes affect NTCP models. Firstly, the fractionation scheme used
can change a tissue’s dose response to the physical dose delivered and consequently
the incidence and severity of toxicities. Although fractionation can be accounted for
by applying the LQ model, this model cannot be extrapolated to very low or high
doses per fraction (see Section 6.2.2). Thus alternative models accounting for fraction-
ation may have to be used. Also, HFRT treatments have different dose distributions.
NTCP models derived from SFRT data cannot necessarily be extrapolated to HFRT
and thus new NTCP models for HFRT need to be investigated. Secondly, depending
on the fractionation scheme used, the type of toxicities observed may change. In the
following, both of these effects will be investigated using the data of patients treated
for lung cancer with stereotactic body radiation therapy (SBRT), which is a common
form of HFRT (see 3.4.2).
In section 6.2, NTCP is modelled for pneumonitis after lung SBRT. Two different
models accounting for fractionation effects were used: The classic LQ model and an al-
ternative model, the low dose hyper-radiosensitivity (LDHRS) model. Model param-
eters are compared to SFRT and biological rationale and implications of the LDHRS
61
Chapter 6. Influence of Fractionation
model are discussed.
While radiation pneumonitis is a major side effect during lung SFRT, chest wall
and extrapulmonary soft tissue complications can emerge during HFRT. In section
6.3, NTCP models are created for toxicities related to the chest wall, including chest
wall pain, myositis, and rib fractures.
6.2 Normal Tissue Complication Probability Modelling
of Radiation Pneumonitis for Hypofractionated Ra-
diation Therapy
Publication: Normal Tissue Complication Probability Modeling of radiation pneu-
monitis following hypo-fractionated radiotherapy 1
6.2.1 Background
Radiation pneumonitis (RP) is a severe complication of radiotherapy of the lungs that
can significantly impact a patient’s quality of life or even have fatal consequences (Bil-
liet et al., 2014). Consequently, prediction and NTCP modelling of RP is important
to ensure optimal treatment of lung cancer and other sites involving radiation to the
lungs. Several studies have modelled NTCP of RP in SFRT of lung (Seppenwoolde
et al., 2003; Sonke et al., 2011; Tucker et al., 2008). In recent years, SBRT has been in-
creasingly used for the treatment of early stage lung tumors, because of the increased
biological effectiveness of large doses per fraction in tumor control (Beli et al., 2010).
However, there is a concern that lung SBRT will lead to increased toxicity in nor-
mal tissue, although improved targeting may reduce RP (Ricardi et al., 2015). A meta-
analysis by Brock et al. showed symptomatic RP grade ≥2 ranging from 0 % - 29 %
(6.5 % on average) in hypo-fractionated patients (Brock et al., 2008). Although Brock
et al. conclude that toxicities of SFRT and SBRT are roughly consistent, a just com-
parison would require that biologically effective dose (BED) to the lungs is taken into
consideration. Since BED in the lungs can be drastically different in SBRT patients, it
is also not certain that NTCP models derived from SFRT data can be extrapolated to
SBRT. Studies that model NTCP for SBRT of lung are scarcer than those for SFRT, pre-
sumably due to SBRT being introduced into common clinical practice more recently.
Borst et al. and Sonke et al. have modelled NTCP for hypofractionated data (Sonke
et al., 2011; Borst et al., 2009). Both studies have modelled hypofractionated data based
on the mean lung dose and have corrected dose for fractionation effects using the LQ
model.
1Submitted to the International Journal of Radiation Oncology, Biology, Physics
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6.2.2 Induced Repair and the Low Dose Hyperradiosensitivity Model
The LQ model described in section 3.4.2 is currently the standard model used to cor-
rect dose for fractionation effects. However, it has been shown that the LQ model is not
accurate at very high and very low doses per fraction (Andisheh et al., 2013; Hamilton
et al., 1996). The LDHRS model has been proposed as an alternative to the LQ model
by Singh et al. to account for the effects of low doses per fraction (Singh et al., 1994).
The LDHRS model generally follows the assumptions of the LQ model, but addition-
ally assumes that cell repair is not properly triggered at low doses per fraction (/ 0.5
Gy) which leads to increased damage at these doses. BED in the LDHRS model is
calculated as
BEDLDHRS = nd
(
1 +
(αs
α
− 1
)
exp
(
− d
dc
)
+
d
α
β
)
, (6.1)
where α, β are the coefficients of the linear and quadratic components of cell kill as
defined in the LQ model (see equation 3.7), and n and d denote the number of fractions
and dose per fraction, respectively. The parameter αs determines the sensitivity to
radiation in the low-dose per fraction regime, and dc is the threshold dose for induced
repair. Note that the LDHRS model converges to the LQ model for αs → α. Figure 6.1
shows the surviving fraction SF for the LDHRS model and the LQ model. As shown,
the surviving fraction SF predicted by the LDHRS model is lower than predicted by
the LQ model for low doses per fraction.
Similarly to the LQ model, normalized total dose (NTD) can also be defined for the
LDHRS model
NTD2,LDHRS = nd
1 + (αsα − 1) exp(− ddc ) + dαβ
1 +
(
αs
α
− 1
)
exp(− 2
dc
) + 2α
β
 . (6.2)
Hypersensitivity and induced repair has been shown to exist in vitro, mainly in tumor
cells (Joiner et al., 1996), but there is also evidence that the effect exists in human lung
cell lines (Singh et al., 1994). Hypersensitivity may exist in vivo, as was demonstrated
for mouse skin (Joiner et al., 1986).
6.2.3 Methods and Materials
This study compares Lyman and logistic regression NTCP models for predicting RP
in hypo-fractionated lung data, including models based on mean lung dose (MLD),
equivalent uniform dose (EUD) and cutoff dose volumes (VDc). Both the LQ model
and the LDHRS model are used to correct for fractionation effects.
Patient Data
Lung dose volume histograms (DVHs) and radiation pneumonitis toxicity scores of
377 patients from 5 institutions participating in the Elekta lung research consortium
treated between 2005 and 2011 were investigated in this study. All patients were
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[Gy]
Figure 6.1: Surviving fraction SF after dose D, as predicted by the linear quadratic
(LQ) model (orange) and the low dose hyperradiosensitivity (LDHRS) model (blue).
The parameters used were α = 0.15 Gy−1, β = 0.07 Gy−2, αs = 1.19 Gy−1, and dc = 0.58
Gy (Singh et al., 1994).
treated with SBRT treatment schemes in 3-10 fractions with between 5 to 18 Gy per
fraction up to a maximum total physical dose of 64 Gy (Table 6.2). The median pre-
scription dose was 54 Gy and the median number of fractions was 3. Either three
dimensional conformal radiation therapy (3D-CRT) or intensity modulated radiation
therapy (IMRT) plans were used for treatment with 5-11 beams. Patients who had mul-
tiple treatments were excluded. For all patients, the gross tumor volume (GTV) was
contoured based on planning computed tomography (CT) scans which were either
average CTs, mid ventilation CTs or four dimensional computed tomography (4D-CT)
scans. Internal target volumes (ITVs) were defined either by averaging the GTV con-
tours from all 10 phases of a 4D-CT, combining maximum inspiration and expiration
GTV contours, or as an average GTV on midventilation CTs. Three institutions did not
extend the ITV to a clinical target volume (CTV), while in the remaining 2 institutions
ITV to CTV margins of 4-7 mm were used. Planning target volume (PTV) margins
were isotropic 5 mm in all institutions. All dose distributions were calculated with
Pinnacle’s collapsed cone algorithm (Philips Pinnacle3, Philips Healthcare, Andover,
MA). The lung DVHs were determined based on the contour of both lungs exclud-
ing the GTV. Radiation pneumonitis was scored based on the Common Terminology
Criteria for Adverse Events (CTCAE) version 3.0. The endpoint of this study was ra-
diation pneumonitis grade 2 and higher. The follow-up (FU) schedule recommended
FU visits every 3 to 6 months during the first two years after treatment. Patients with
a follow-up of less than 6 months were not included in this study.
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Prescribed dose
[Gy]
Number of fractions Dose per fraction
[Gy]
Number of patients
54 3 18 176
48 4 12 119
60 5 12 34
37.5 3 12.5 15
60 8 7.5 8
60 3 20 7
50 10 5 5
48 8 6 4
40 5 8 2
45 3 15 2
60 10 6 1
36 2 18 1
55 5 11 1
64 8 8 1
50 5 10 1
Table 6.1: Prescribed physical dose and fractionation.
Dose Volume Histograms
To account for the different fractionation schemes, all DVHs were converted to normal-
ized total dose (NTD2) for each dose bin using the LQ model (equation 3.8) and the
LDHRS model (equation 6.2). The parameter dc was fixed to 0.58 Gy for the LDHRS
model. The parameters α and β were fixed to 0.15 Gy−1 and 0.07 Gy−2, respectively for
both the LQ and the LDHRS model, following parameters fitted to the LDHRS model
by Singh et al. (Singh et al., 1994).
Normal Tissue Complication Probability Modelling
NTCP was modeled using the Lyman model (Equation 4.9) and the cutoff dose logistic
regression (CDLR) model (Equation 4.7). The Lyman model described in Chapter 4
was used with different summary measures X :
t =
X −X50
mX50
,
where X was either EUDNTD,LQ, EUDNTD,LDHRS, MLDNTD,LQ or MLDNTD,LDHRS. X50
denotes the respective X causing a 50 % chance of experiencing a complication. EUD
was calculated using the generalized equivalent uniform dose (gEUD) using equation
4.6. The CDLR model was used with cutoff doses Dc converted to NTD (Söhn, Yan,
Liang, Meldolesi, Vargas and Alber, 2007). Overall five different combinations of the
two NTCP models with either the LQ model or the LDHRS model were investigated:
1. the Lyman model with the MLD calculated based on the LQ model (Lyman MLD
LQ model),
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2. the Lyman model with gEUD calculated based on the LQ model (Lyman EUD
LQ model),
3. the Lyman model with the MLD based on the LDHRS model (Lyman MLD
LDHRS model),
4. the CDLR model with VDc based on the LQ model (CDLR LQ model),
5. the CDLR model with VDc based on the LDHRS model (CDLR LDHRS model).
Optimal NTCP parameter estimates and confidence intervals (CIs) of the NTCP mod-
els for radiation pneumonitis were determined using maximum likelihood estimation
(MLE) (section 4.5.1) and the profile likelihood method (section 4.8.2). Goodness of fit
of data to the model was evaluated using the Hosmer-Lemeshow goodness of fit test
(section 4.7). The NTCP models were compared with each other using the corrected
Akaike information criterion (AICc) described by equation 4.18. The three nested Ly-
man models were further compared using the likelihood ratio test (section 4.6) to test if
additional model parameters yield significant improvement. In the same manner, the
two CDLR models were compared. All calculations were performed in Mathematica
(Mathematica v. 9.0, Wolfram Research Inc., Champaign, IL).
6.2.4 Results
Patient Characteristics
28 (7.4%) of the patients investigated experienced pneumonitis of grade ≥ 2. Out of
these 28 cases, 2 patients had pneumonitis grade 5, no patient had pneumonitis grade
4, 4 patients had pneumonitis grade 3, and 22 patients had pneumonitis grade 2. The
median follow-up was 2.07 years. These data and other patient characteristics are
summarized in Table 6.2.
Normal Tissue Complication Probability Models
The optimal NTCP model parameters are shown in Table 6.3. The Hosmer-Lemeshow
goodness of fit values indicate that all five models yielded acceptable fits to the data
(pHL >0.05, 6 bins). The CDLR LDHRS model showed the best performance in terms
of the log-likelihood compared to the Lyman EUD LQ, the Lyman MLD LQ model,
Lyman MLD LDHRS model and the CDLR LQ model. When comparing the mod-
els with adjustments for the number of parameters used, the Lyman MLD LQ model
shows the best AICc. A likelihood ratio test did not show a significant difference be-
tween the Lyman EUD LQ, the Lyman MLD LDHRS and the Lyman MLD LQ models.
Furthermore, there was no significant difference between the nested CDLR models
according to the likelihood ratio test. The optimal NTCP curves for all three Lyman
models and binned data are shown in Figure 6.2. NTCP curves for the CDLR models
are shown in Figure 6.3.
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Figure 6.2: Optimal normal tissue complication probability (NTCP) curve and binned
MLD/EUD data for the Lyman MLD LQ model (left), the Lyman EUD LQ model and
the Lyman MLD LDHRS model. The error bars indicate the 95 % binomial confidence
intervals from binning the data.
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Figure 6.3: Optimal normal tissue complication probability (NTCP) curve and binned
VDc data for the CDLR LQ model and the CDLR LDHRS model. The error bars indicate
the 95 % binomial confidence intervals from binning the data.
6.2.5 Discussion
In this study NTCP was modelled for radiation pneumonitis after hypo-fractionated
radiation therapy (RT) of lung cancer using various NTCP models. Two different cell
survival models, (1) the LQ model and (2) the LDHRS model, were used to account for
dose fractionation effects. The Lyman MLD LQ model showed the minimal AICc, due
to a large likelihood and small number of parameters used in the model. However, the
difference in AICc between the three Lyman models is small, which means that none
of the models is preferable over the others in terms of AICc. The likelihood ratio test
suggests that the additional parameters of the Lyman EUD LQ and the Lyman MLD
LDHRS model do not lead to significantly improved model performance compared to
the Lyman MLD LQ model. Similarly, the improvements in terms of log likelihood
of the CDLR LDHRS model compared to the CDLR LQ model are not significant.
However, although the LDHRS model does not yield significant improvement over
the LQ model in terms of NTCP model fit, the use of the LDHRS model may enable the
Characteristic
Age (median, range) 75.2 yrs (42yrs – 93.5 yrs)
Gender 199 female
178 male
FU time (median, range) 25 months (6.2 months – 84.5 months)
Pneumonitis grade ≥2:
0 or 1 349 (92.6 %)
2 22 (5.8 %)
3 4 (1.1 %)
4 0 (0.0 %)
5 2 (0.5 %)
Maximum tumor diameter (mean, SD) 2.59 cm ± 1.15 cm
Biopsy proven 253 (67.1 %)
Rx dose (median, range) 54 Gy (36 Gy – 64 Gy)
Table 6.2: Patient characteristics.
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description of SBRT and SFRT with a single set of parameters, which will be discussed
below.
Implications of using the LDHRS model compared to the LQ model
The LDHRS model may yield an alternative biological explanation for the low values
of the volume-effect parameter, a, obtained for the Lyman EUD LQ model. The value
for the volume effect parameter a used for EUD calculation determined in this study
for SBRT was 0.3, whereas most studies investigating pneumonitis for SFRT report
values close to or slightly larger than 1 (Seppenwoolde et al., 2003; Martel et al., 1994).
It should be noted, however, that the upper confidence limit for a (0.0, 1.8) in this study
includes those values. For low values of a (0<a<1) the EUD becomes smaller, or more
influenced by low doses. This makes little sense in terms of the parallel versus serial
tissue architecture interpretation of a that is cited in the literature (Li, Alber, Deasy,
Jackson, Jee, Marks, Martel, Mayo, Moiseenko, Nahum and others, 2012). The LDHRS
theory, however, may yield a better interpretation, since it assumes that low doses per
fraction have a larger influence on cell survival, due to insufficient triggering of repair
processes.
Figure 6.4 (a) and (b) show the theoretical ratio of the surviving fraction (SF) for
different iso-doses in lung with various fractionation schemes to a standard fractiona-
tion scheme of 30 fractions and 2 Gy per fraction for the LQ and the LDHRS models,
respectively. The LDHRS model predicts a surviving fraction for HFRT (i.e. < 30 frac-
tions) that is higher compared to the standard fractionation (30 fractions). At fractions
used in the majority of SBRT cases in this study (3-5 fractions), the effect can be seen
for total doses less than 20 - 25 Gy. The LQ model, on the other hand, always predicts
Model Parameter estimates and CI LL AICc pHL
Lyman MLD LQ MLD50,NTD2 = 50.1 (28.8,∞);
m = 0.55 (0.44, 0.69)
-98.3 200.6 0.7
Lyman EUD LQ a = 0.3 (0.0, 1.8);
EUD50,NTD2 = 13.2 (7.2,∞);
m = 0.57 (0.45, 0.71)
-97.9 201.8 0.4
Lyman MLD LDHRS MLD50,NTD2 = 35.4 (23.2,∞);
m = 0.47 (0.35, 0.9);
αs = 4.9 (0.1,∞)
-97.8 201.7 0.3
CDLR LQ Dc,NTD2 = 30.6 Gy (0,∞);
β0 = -3.27 (-3.93, -2.64);
β1 = 0.10 (0.01, 0.59)
-98.2 202.5 0.5
CDLR LDHRS Dc,NTD2 = 20.3 Gy (10.4 Gy, 64.3 Gy);
β0 = -3.35 (-4.26, -2.51 );
β1 = 0.11 (0.01, 0.38);
αs = 4.9 (0.1,∞)
-97.2 202.4 0.4
Table 6.3: Optimal normal tissue complication probability (NTCP) model parameters,
log-likelihood values, AICc values and Hosmer-Lemeshow goodness of fit p-values.
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lower survival for the same dose delivered in smaller number of fractions compared
to the standard fractionation. Considering the heterogeneous dose distribution (0 Gy -
60 Gy) in lung during typical SBRT, a large volume of normal lung tissue is irradiated
with doses≤ 25 Gy. Therefore, lung NTCP modelling using the LQ model would over-
estimate the BED and NTD corresponding to physical doses ≤ 25 Gy for SBRT, which
would lead to an increase of the MLD50,NTD2 , EUD50,NTD2 and NTD corrected cut off
doses obtained via NTCP modelling. At the same time, the LQ model may potentially
underestimate the NTD for SFRT, as in SFRT more volume is irradiated with low doses
per fraction. Thus, MLD50,NTD2 , EUD50,NTD2 and NTD corrected cut off doses could be
closer than predicted by the LQ model. This could be an indication that both SBRT
and SFRT can be described by the same lung NTCP model when LDHRS is used to
calculate BED or NTD for lung tissue.
Comparison with Other Studies on Lung Stereotactic Body Radiation Therapy
Comparison of NTCP model results to other studies is generally difficult, because the
populations may differ in a variety of different characteristics, and many studies use
different values for the α
β
ratio. Borst et al. modelled NTCP for 128 hypo-fractionated
patients treated with 3D-CRT using the Lyman MLD model with NTD calculated with
the LQ model and an α
β
ratio of 3 Gy (Borst et al., 2009). They obtained an MLD50,NTD2
of 19.6 Gy (95 %CI: 16 - 30 Gy) and m=0.43 (0.33 - 0.59) which is much lower than
the 50.1 Gy (95 % CI: 28.8-∞ Gy) determined in this study. However, the study by
Borst et al. uses the National Cancer Institute Common Toxicity Criteria (NCI-CTC)
and Southwest Oncology Group (SWOG) criteria for scoring pneumonitis, rather than
the CTCAE. Differences in scoring criteria can lead to differences in NTCP parameter
estimates as was demonstrated by Tucker et al. (Tucker et al., 2010). Furthermore, Borst
et al. remark that their sample size is relatively small. They also determined a best fit
cutoff dose and found a Dc,NTD2 of 50 Gy to yield the best fit, which is higher than
the optimal cutoff dose of 30.6 Gy determined in this study based on the LQ model.
This discrepancy however, can be attributed to the different α
β
ratio of roughly 2.1 Gy
used in this study, which was the α
β
determined by Singh et al. (Singh et al., 1994).
When using an α
β
ratio of 3 Gy an optimal cutoff dose of 57 Gy was obtained. Sonke et
al. also modelled NTCP using the LQ model for SBRT patients who partially overlap
with the group of patients considered in this study (Sonke et al., 2011). They calcu-
lated MLD50,NTD2 = 45 Gy (95 % CI, 27-85 Gy), and m = 0.52 (95 % CI, 0.4-0.69), which
is similar to the values determined in this study and also much larger than the results
obtained by Borst et al. The two studies also come to different conclusions regarding
whether hypo-fractionated and standard fractionated patients can be described with
the same model. While Borst et al. do not find a significant difference between models
derived from standard fractionated data, Sonke et al. concluded that there was a sig-
nificant difference between SBRT and SFRT. However, neither of the two studies used
matched samples of patients treated with SBRT and SFRT and therefore it is not clear
whether the data is comparable. Differences in follow up or other covariates could
possibly explain the difference in results. The small differences between NTCP pa-
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rameters determined in the study performed by Sonke et al. and this study are due to
different α
β
ratios. When NTCP for the patients in this study was modelled with an α
β
ratio of 3 Gy, which has been used by Sonke et al., similar parameters were obtained
(MLD50,NTD2 = 44.1 Gy; m = 0.55; LL = -98.3).
Comparison to Standard Fractionated Radiation Therapy
Several studies have shown that radiation pneumonitis in SFRT is best associated with
V20Gy and MLD (Kong et al., 2006; Graham et al., 1999; Claude et al., 2004).
The optimal cutoff dose obtained for the LQ model is higher than the frequently
cited V20Gy for SFRT, but is within the range of other published data for lung SFRT
(Yorke et al., 2005) and V20Gy is within the confidence interval determined in this study.
When the LDHRS model was used, V20.6Gy was found to be the optimal cutoff dose in
this study.
Sonke et al. have found a MLD50,NTD2 of 28.5 Gy for a standard fractionated dataset
using the LQ model (Sonke et al., 2011). This is significantly lower than the MLD50,NTD2
determined for hypo fractionated patients in their and this study, when the LQ model
was used for the NTD calculation. The MLD50,NTD2 determined for the LDHRS model
(35.4 Gy), however, was much closer to typical MLD50 values determined for SFRT
(Seppenwoolde et al., 2003; Kwa et al., 1998). This is an indication that the LDHRS
model could resolve the issue of different MLD50 obtained for SFRT and SBRT and
the LDHRS model may be capable of describing both treatment techniques with the
same NTCP model. Since the LDHRS model would also affect the DVHs of standard
fractionated patients, this is only an indication. In order to estimate how the LDHRS
model may influence SFRT DVHs, the mean MLDNTD2 for all patients in this cohort
were calculated with the LQ model and the LDHRS model, assuming that they were
given in 30 fractions, using the optimal αs = 4.6 Gy−1 determined in this study. The
results were MLDNTD2,LQ,30 = 3.3 Gy ± 1.3 Gy, MLDNTD2,LDHRS,30 = 22.5 Gy ± 6.3 Gy.
Thus, the MLD50 for standard fractionated patients is likely going to increase when
modelled with the LDHRS model. However, for a general comparison of SFRT data
and SBRT data, a matched pair analysis should be performed to ensure that the popu-
lations are comparable in terms of other patient characteristics such as treatment tech-
nique, smoking, pre-existing fibrosis, age, gender, race.
6.2.6 Conclusions
Both the LQ model and the LDHRS model yield acceptable NTCP models for radiation
pneumonitis when fit to DVHs and toxicity data of hypo-fractionated lung RT. How-
ever, the LQ model uses less parameters and thus may be statistically preferable. The
LDHRS model may offer a biological explanation for a possible increased influence
of low doses per fraction on pneumonitis. Unfortunately, due to the large confidence
intervals obtained in this study, the effect could not be verified. Furthermore, the
LDHRS model may be able to describe SBRT and SFRT with the same model. In the
future, further investigations on the validity of the LDHRS model are necessary and
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(a) LQ model (b) LDHRS model
Figure 6.4: Ratio of surviving fractions of a total physical dose of X Gy, to X Gy given
in 30 fractions as a function of the number of fractions, for X= 10 Gy, 15 Gy, 20 Gy, 25
Gy, 30 Gy, 35 Gy and 40 Gy for (a) the linear quadratic (LQ) model and (b) the low
dose hyperradiosensitivity (LDHRS) model.
studies comparing hypo-fractionated NTCP to standard fractionated RT for matched
datasets should be undertaken.
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6.3 Normal Tissue Complication Probability Models for
Chest Wall Related Toxicities
6.3.1 Background
The use of SBRT for the treatment of non-operable lung tumors has markedly im-
proved local control in this patient population, and is now considered as a potential
treatment option even for operable lung tumors. However, investigations are still un-
derway to establish whether SBRT is sufficiently safe for normal tissues. Several insti-
tutions report an increased incidence of toxicities related to the chest wall, especially
chest wall pain and rib fractures (Mutter et al., 2012; Voroney et al., 2009; Bongers et al.,
2011). Thus, various studies have sought to find dose volume predictors for chest wall
toxicities after lung SBRT (Murray et al., 2016; Thibault et al., 2016; Mutter et al., 2012;
Voroney et al., 2009; Bongers et al., 2011; Andolino et al., 2011). However, no standard
dose volume constraints for treatment planning were established so far and it is not
clear if more effort should be undertaken to spare the chest wall (Thibault et al., 2016).
The majority of aforementioned studies focus on cutoff dose volumes constraints, and
NTCP models of chest wall toxicities are scarce. Modelling NTCP for chest wall toxic-
ities can be challenging, as the chest wall and ribs are not typically contoured for lung
SBRT, and thus have to be contoured retrospectively. Furthermore, chest wall toxici-
ties are not always documented properly. The aim of this study was to model NTCP
for chest wall toxicities in lung SBRT patients using four different NTCP models.
6.3.2 Methods and Materials
Patient Data
In this study, DVHs of 70 patients treated for early stage non small cell lung cancer
or limited pulmonary metastases were evaluated to create NTCP models for toxicities
related to irradiation of the chest wall. All patients were treated with SBRT between
2006 and 2012. 25 patients were prescribed 60 Gy to the tumor in 5 fractions of 12 Gy
and the remaining 45 patients were prescribed 48 Gy given in 4 fractions. The endpoint
of this study were chest wall toxicities grade ≥ 2, which included chest wall pain,
myositis (muscle inflammation) and rib fractures. All toxicities were scored using the
CTCAE version 3.0. Patients with FU times of less than 6 months were excluded from
the study.
The GTV was contoured on breathing phase 0 of a 4D-CT of the thorax with 10
phases and then propagated to the other 9 breathing phases. The 10 contours were
merged to form an ITV and then a 4 mm margin was added to create the CTV contour.
The PTV was contoured by adding a 5 mm margin to the CTV. Three chest wall con-
tours (CW1cm, CW2cm, CW3cm) were created in Pinnacle (Philips Pinnacle3, Philips
Healthcare, Andover, MA) using a semi automated in-house Pinnacle script. CW1cm,
CW2cm, and CW3cm were defined as 1 cm, 2 cm and 3 cm rings extending radially
outward from the lung and chest wall interface (Figure 6.5). The dose matrix and
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Figure 6.5: Chest wall contours CW1cm (red), CW2cm (blue) and CW3cm (green)
extending radially outward from the chest wall lung interface (green).
DVHs were calculated using Pinnacle’s collapsed cone (CC) algorithm. Mathematica
(Wolfram Research, Inc., Mathematica, Version 9.0.1, Champaign, IL (2013)) was then
used to convert DVHs to BED using the LQ model (Equation 3.7) with an α
β
ratio of
3 Gy. The CW1cm contour was then used for NTCP modelling as dose volume pa-
rameters in this contour were shown to be most strongly correlated with chest wall
toxicities (Mangona et al., 2013).
Normal Tissue Complication Probability Models
The Lyman model (Equation 4.9) and the CDLR model (Equation 4.7) were used to
model NTCP. The summary measures used were mean chest wall dose (MCWD) and
EUD for the Lyman model (Lyman MCWD model, Lyman EUD model), and VDc for
the CDLR model (CDLR model). All of these summary measures were calculated from
DVHs that were first converted to BED. Additionally, for the CDLR model, VDc calcu-
lated using physical dose was used (CDLR PHYS). The optimal model parameters
were determined using MLE as described in Section 4.5.1. CIs were calculated using
the likelihood profile method (Section 4.8.2). Goodness of fit was evaluated using the
Hosmer Lemeshow goodness of fit test (Equation 4.19).
6.3.3 Results
Patient Characteristics
Of the 70 patients used in this study, 25 (35.7 %) experienced chest wall toxicities of
grade ≥ 2. The median FU was 2.3 years with a range of 0.5 years to 6.5 years. The
median age was 77 years with ages ranging from 57 years to 93 years. 41 patients were
female and 29 patients were male.
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Model Parameter estimates and CI LL AICc pHL
Lyman MCWD MCWD50,BED = 23.8 (16.8 Gy, 59.0 Gy);
m = 0.93 (0.58, 2.32)
-42.5 89.2 0.7
Lyman EUD a = 2.15 (0.40,∞);
EUD50,BED = 72.2 Gy (7.7 Gy,∞);
m = 0.77 (0.41, 2.04)
-42.2 90.7 0.6
CDLR Dc,BED = 212.9 Gy (22.2 Gy, 301.1 Gy);
β0 = -1.24 (-2.96, -0.55);
β1 = 0.34 (0.06, 0.60)
-41.9 90.3 0.3
CDLR PHYS Dc = 39.9 Gy (8.4 Gy, 57.8 Gy);
β0 = -1.18 (-3.20, -0.47);
β1 = 0.19 (0.02,0.40)
-43.0 92.4 0.3
Table 6.4: Optimal normal tissue complication probability (NTCP) model parameters,
log-likelihood values, AICc values and Hosmer-Lemeshow goodness of fit p-values
for chest wall toxicities (chest wall pain, rib fractures, myositis) grade ≥ 2.
Normal Tissue Complication Probability Models
The optimal NTCP model parameters, CIs, log likelihood, AICc and Hosmer-Lemeshow
goodness of fit p-values are shown in Table 6.4. The optimal NTCP curves together
with the binned toxicity and DVH data are shown in Figure 6.6a, Figure 6.6b, Fig-
ure 6.7a, and Figure 6.8a for the Lyman MCWD, the Lyman EUD, the CDLR and the
CDLR PHYS model, respectively. According to the Hosmer Lemeshow goodness of
fit test, all models fit the data well (pHL > 0.05). The Lyman MCWD model had the
lowest AICc, however the AICc values of all models were similar. Table 6.5 shows the
physical dose values corresponding to the BED values given in 4 and 5 fractions.
Model BED 5 fractions 4 fractions
CDLR 212.9 Gy 49.5 Gy 44.9 Gy
Lyman MCWD 23.8 Gy 12.8 Gy 11.9 Gy
Lyman EUD 72.2 Gy 26.3 Gy 24.0 Gy
Table 6.5: Conversion of biologically effective dose (BED) with α
β
= 3 Gy to physical
dose given in 5 and 4 fractions.
6.3.4 Discussion
In this study, NTCP models for chest wall toxicity grade ≥ 2 were created using
CW1cm DVHs. All derived models fit the data well. The CDLR model using BED
DVHs obtained the highest likelihood, but when corrected for the number of parame-
ters using AICc, the Lyman MCWD model showed the best performance. The CDLR
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(a) Lyman MCWD model (b) Lyman EUD model
Figure 6.6: Optimal normal tissue complication probability (NTCP) curve and binned
MLD and EUD data for the Lyman model. The error bars indicate the 95 % binomial
confidence intervals from binning the data.
(a) CDLR model (b) Log likelihood LL versus Dc
Figure 6.7: Optimal normal tissue complication probability (NTCP) curve and binned
VDc data for the CDLR model using BED. The error bars indicate the 95 % binomial
confidence intervals from binning the data.
(a) CDLR PHYS model (b) Log likelihood LL versus Dc
Figure 6.8: Optimal normal tissue complication probability (NTCP) curve and binned
VDc data for the CDLR model using physical dose (CDLR PHYS). The error bars indi-
cate the 95 % binomial confidence intervals from binning the data.
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model using physical dose (CDLR PHYS) performed worst both in terms of log likeli-
hood and AICc. The AICc values for all models, except the CDLR PHYS model were
similar.
For the Lyman EUD model, an optimal value for the volume effect parameter a of
2.15 was obtained, which suggests that chest wall toxicities are potentially subject to
a volume effect. Since the CI for the volume effect parameter a is large (0.4, ∞), the
value will have to be confirmed in future studies with more patients. This study is a
preliminary study and is limited by the small number of patients used for the study,
leading to large CIs. However, the incidence of chest wall toxicities was relatively high
and thus allowed for NTCP modelling.
Several studies have investigated dose volume predictors for chest wall toxicities.
Mutter et al. investigated predictors for chest wall pain in SBRT patients receiving 40-
60 Gy in 3-5 fractions (Mutter et al., 2012). They report an estimated 2 year actuarial
incidence of chest wall toxicities of 39% which is similar to the incidence of 35.6 % in
this study. Mutter et al. found the volume receiving a physical dose of 30 Gy or higher
to be the best predictor for chest wall, while this study found a physical cutoff dose of
39 Gy to yield the largest log likelihood. However, V30Gy is within the CI obtained in
this study and the log likelihood profile of the cutoff dose Dc shows a plateau between
20 Gy and 40 Gy, indicating that values in that whole range may all yield acceptable
NTCP models (Figure 6.8b). Thus, the results obtained in this study seem roughly
consistent with Mutter et al.
Mutter et al. converted DVHs to BED using α
β
ratios ranging from 2 - 10 Gy, and
conclude that there is no advantage of biologically corrected dose over physical dose.
This study, in contrast, showed that the CDLR BED model had superior AICc over the
CDLR phys model with physical dose. However, there were several differences be-
tween the two studies that could lead to discrepancies. Mutter et al. used the NCI-CTC
scale, and extended the chest wall contour by 2 cm and 3 cm, while this study used
CTCAE for toxicity grading and focused on CW1cm. Currently, there is no widely ac-
cepted clinical standard on how to contour the chest wall and ribs and future studies
will have to determine appropriate contouring.
Thibault et al. investigated patient characteristics associated with chest wall toxic-
ities. They found female gender, osteoporosis, a tumor position adjacent to the chest
wall (within 5 mm), and several DVH parameters (Dmax, D1cm3 , D2cm3 , D5cm3 , V30Gy,
V40Gy, V50Gy) to be predictive for rib fractures in a univariate analysis (Thibault et al.,
2016). After multivariate analysis, only tumor position adjacent to the chest remained
and they concluded that no DVH parameter was able to predict rib fractures indepen-
dently. Their results indicate that patient characteristics may need to be taken into
account when comparing SBRT populations and when modelling larger cohorts in the
future.
Andolino et al. determined predictors for rib fractures and chest wall pain using the
CTCAE for SBRT patients treated with SBRT for lung and liver cancer (Andolino et al.,
2011). They used the median effective concentration dose–response model, which cor-
relates a cutoff dose volume with the risk of toxicities occurring. They determined
that the volume of chest wall receiving 25 Gy - 60 Gy physical dose is associated with
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a significantly higher incidence of chest wall toxicities, which is consistent with the
results obtained in this study. However, in contrast to this study, they used CW3cm
and scored all chest wall toxicities including grade 1.
Murray et al. report evidence that small hot spots are associated with chest wall
pain grade ≥ 2. They looked for predictors for CTCAE grade ≥ 2 chest wall pain in
SBRT patients treated with 55 Gy in 5 fractions and found that tumor size and Dmax
received by 1 cm3 of the chest wall and tumor size were predictive of chest wall pain.
6.3.5 Conclusion
In this study, NTCP was modelled for chest wall toxicities grade ≥ 2 after lung SBRT.
The Lyman model based on the mean dose to the chest wall performed the best in
terms of AICc, but all BED based models fit the data well and had similar AICc val-
ues, except for the model based on physical dose. Correcting for fractionation by using
BED DVHs rather than physical DVHs to model NTCP is advantageous. However,
future studies need to determine the most appropriate values for the α
β
ratio for chest
wall toxicities. Furthermore, future prospective investigations with larger patient pop-
ulations should be undertaken to confirm the results of this study and also to establish
a consensus on how to contour the chest wall. Since NTCP models predicting chest
wall toxicities are scarce, this preliminary study could give valuable information on
the dose response of chest wall toxicities and potentially aid in finding acceptable clin-
ical dose constraints for the chest wall during lung SBRT.
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Publication: Stereotactic radiotherapy of intrapulmonary lesions: comparison of dif-
ferent dose calculation algorithms 1
7.1 Background
The goal of normal tissue complication probability (NTCP) modelling is to create a
relationship that describes the probability of a patient experiencing side effects as a
response to the radiation dose received by a structure. Thus, in order to obtain an
accurate model, it is of importance that the dose distributions used for modelling re-
flect the actual dose delivered to the patient. Improvements in radiation therapy (RT),
such as image guided radiation therapy (IGRT) and adaptive radiation therapy (ART),
have reduced setup errors and errors resulting from anatomical changes. Thus these
and other advances in radiation therapy have reduced the difference between planned
dose and delivered dose. Another factor in correctly assessing the dose delivered to
the patient is the choice of the dose calculation algorithm used to calculate the planned
dose. As described in Chapter 3, there are three main types of algorithms used in con-
temporary RT: pencil beam (PB) based algorithms, collapsed cone (CC) based algo-
rithms, and Monte Carlo (MC) simulations. These algorithms differ in how accurately
they calculate dose. The PB based algorithms used to serve as the standard algorithms
in treatment planning due to their calculation speed. However, it is well known that
the PB algorithms lack accurate modelling of lateral scattering and backscatter, be-
cause they neglect tissue density inhomogeneities other than in the direction of the
beam and assume water density instead (see Section 3.3). In contrast, CC and MC in-
clude more accurate inhomogeneity corrections/modelling (Ahnesjö and Aspradakis,
1Reprinted (adapted) with permission from “Stereotactic radiotherapy of intrapulmonary lesions: com-
parison of different dose calculation algorithms for Oncentra MasterPlan R©” by Troeller, A., Garny, S., Pach-
mann, S., Kantz, S., Gerum, S., Manapov, F., Ganswindt, U., Belka, C., Söhn, M., 2015. Radiat. Oncol.
10. doi:10.1186/s13014-015-0354-3
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1999). The use of more accurate dose calculation algorithms, such as CC and MC,
has increased during the past few years due to increased speed of the algorithms and
availability of advanced computational technology. A popular choice for dose cal-
culation are now CC based algorithms that approximately model lateral scattering and
backscatter via density dependent anisotropic rescaling of pre-calculated point kernels
for effects from secondary particle transport. MC simulations, which explicitly model
particle interactions and transport in the patient, are generally considered the gold
standard of dose calculation.
Differences in dose calculation accuracy in the patient between the different algo-
rithms can be expected to be most predominant in anatomic regions with large local
tissue density inhomogeneities and density discontinuities such as for small lung le-
sions surrounded by low density lung tissue. When stereotactic body radiation ther-
apy (SBRT) of intrapulmonary lesions was first introduced into routine clinical treat-
ment, most institutions calculated dose distributions using dose calculation programs
based on PB type algorithms. However, as indicated above, it is now widely and clin-
ically accepted that dose calculation algorithms of PB type do generally not provide
enough accuracy for dose calculation in inhomogeneous tissue (Krieger and Sauer,
2005; Vanderstraeten et al., 2006). Recent recommendations for the implementation
of SBRT of lung cancer usually include the use of CC or MC algorithms. However,
historically prescription schemes were based on clinical experience with PB. Recent
guidelines such as the International Commission on Radiation Units and Measure-
ment (ICRU) recommend similarly strict requirements for treatment plans calculated
with CC or MC as they do for PB (ICRU-62, Bethesda, Md, USA, 1999). Because of
the insufficient modelling of lateral scattering and backscatter, the dose to the tumor
is usually overestimated when using PB and the same plan may indicate lower dose
when recalculated with CC (Aarup et al., 2009; Dobler et al., 2006). This will lead to
treatment plans with changes in field size and monitor units (MUs) delivered, as well
as changes in dose to organ at risk (OAR) when creating a treatment plan based on a
CC dose calculation algorithm, without proper adjustment of the prescription.
In the following, differences between dose distributions and derived dose volume
parameters calculated with PB and CC are investigated, which are the two dose calcu-
lation algorithms implemented in the clinical three dimensional conformal radiation
therapy (3D-CRT) treatment planning system (TPS) used at the LMU Munich, Oncen-
tra MasterPlanr (OTP). In order to quantify differences between dose distributions
calculated with PB and CC in patients treated at LMU Munich, treatment plans of
patients that received SBRT of intrapulmonary lesions were examined, since these pa-
tients usually have smaller tumors and may show large discrepancies between dose
calculated with PB and CC.
7.2 Methods
The treatment plans of 17 patients treated for small intrapulmonary lesions between
2008 and 2010 were retrospectively evaluated (Table 7.1). For each patient, three com-
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Patient Maximum tumor
diameter (cm)
Total volume
GTV (ccm)
Tumor location Central/peripheral
1 1.6 2.0 RLL peripheral
2 1.6 3.5 RUL central
3 4.1 41.2 RUL peripheral
4 3.1 12.1 LLL peripheral
5 2.8 6.4 R central
6 1.5 1.4 RUL peripheral
7 1.2 4.6 RLL peripheral
8 4.5 3.8 R central
9 1.2 1.2 R central
10 2.6 15.2 RLL peripheral
11 3.0 17.0 LUL central
12 2.5 4.4 RUL peripheral
13 2.5 27.0 RLL peripheral
14 3.9 27.9 RLL peripheral
15 4.6 61.6 RLL central
16 1.8 4.7 RUL peripheral
17 4.0 36.2 LUL peripheral
Table 7.1: Tumor size, volume and location for all patients. For the purpose of this
study tumors that were directly attached to the mediastinum or pleura were defined
as peripheral and all others (fully surrounded by low density lung tissue) as central.
RUL, RLL, LLL, LUL, and R refer to right upper lobe, right lower lobe, left lower lobe,
left upper lobe and right, respectively.
puted tomography (CT) scans (3 mm slice distance) were acquired prior to treatment:
a free-breathing scan, a maximum inhale and a maximum exhale scan. The scans were
then imported to the OTP treatment planning system (Version 4.2, Nucletron). The
gross tumor volume (GTV) was contoured on each of the CT scans and an internal tar-
get volume (ITV) was defined by forming the union of all GTVs. The planning target
volume (PTV) was created from the ITV, by adding a 7 mm margin laterally and 9 mm
in the cranial-caudal direction. For all patients, a cumulative physical dose of up to 60
Gy was prescribed to the PTV in single fractions of 7.5 Gy, such that the 80% isodose
line completely covered the PTV. All dose calculations were performed on the free-
breathing CT scan without density overrides. The 3D-CRT, un-modulated treatment
plans were designed for a Siemens Oncor treatment unit with a 10 mm leaf width multi
leaf collimator (MLC). Mixed photon energy was used (6 and 15 MV) incorporating 7
beams on average. The beam model was verified against experiment and accepted
for clinical use. The dose distributions of the original treatment plans were calculated
using OTP’s enhanced PB algorithm. For the purpose of this study, all plans were re-
calculated with the enhanced CC algorithm implemented in OTP (CCre-calc), without
altering the field shape, field size, beam setup, or monitor units. Furthermore two ad-
ditional plans calculated with CC were created for each patient: A plan that resembles
what would currently be considered acceptable for a patient in the LMU clinic (CCclin)
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and a stricter second plan (CCcov) that obtained coverage similar to the original PB
plan (PB). The former constitutes a clinically accepted compromise that may formally
violate the PTV coverage criteria mentioned above in low density parts of the PTV
where full dose build-up is difficult to realize for physical reasons. The latter was cre-
ated to demonstrate how dose to OARs would change in the hypothetical scenario of
switching from a PB algorithm to a CC algorithm without adapting the criteria for an
acceptable plan.
For the CCclin and CCcov plans MUs as well as field size and shape had to be ad-
justed accordingly. For the CCcov the fields were opened in beam’s eye view (BEV) un-
til coverage was achieved, while for the CCclin the distance between the jaws and the
PTV-outline were not to exceed 1 cm in BEV. All four plans per patient were then com-
pared to each other. Parameters used for comparison were volume coverage (V60Gy),
mean dose (Dmean), dose received by 99% and 1% of the volume (D99 and D1), mini-
mum dose (Dmin), and maximum dose (Dmax) for the GTV, ITV and PTV. Estimated
coverage in dependence on GTV volume was also considered. Furthermore Dmean,
V20Gy and V10Gy to the lungs, Dmean to the heart and Dmax to the spinal cord and esoph-
agus were evaluated. Both lungs were contoured as one organ including the PTV.
The adjusted CCclin and CCcov treatment plans were further analyzed regarding al-
terations of MUs and field size compared to the original PB plan. The influence of
tumor position and movement on coverage was investigated. For the purpose of this
study tumors that were directly attached to the mediastinum or pleura were defined
as peripheral and all others as central. Statistical significance of the differences be-
tween parameters calculated with PB and parameters calculated with CCre-calc, CCclin
and CCcov was determined using the Wilcoxon signed-rank test (p < 0.05 signifies
significant difference). Correlation of the difference in target coverage between PB
and CC (i.e. V60Gy,PB – V60Gy,CC) with the target region of interest (ROI) volumes was
determined using Spearman’s rank correlation coefficient ρ. The significance of the
correlation was verified with Spearman’s rank test, with the null hypothesis H0 that
ROI volume and difference in coverage are independent and alternative hypothesis
Ha that they are dependent. The analysis of the parameters and statistical analyses
was performed in Mathematica (Wolfram Research, Inc., Mathematica, Version 9.0.1,
Champaign, IL, 2013).
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7.3 Results and Discussion
7.3.1 Original Pencil Beam Plan versus the Original Plan Recalcu-
lated with Collapsed Cone (CCre−calc)
For the target structures GTV, ITV and PTV, all evaluated parameters (V60Gy, Dmean,
Dmin, Dmax, D99, D1) were significantly lower (p < 0.001) for the plans that were re-
calculated based on the CC algorithm (CCre-calc) as opposed to the original ones incor-
porating the PB algorithm (PB). All OAR parameters considered in this study (p <
0.01), except Dmax to the spinal cord, were statistically significantly lower when the PB
plan was recalculated with CC. However the differences regarding heart and spinal
cord were of relatively small magnitude and may not be clinically relevant. The re-
sults for all structures are shown in Table 7.2. The GTV, ITV and PTV coverage with
60 Gy and higher as well asD99 and Dmax in dependence on the GTV, ITV and PTV vol-
ume for both PB and CCre-calc treatment plans are shown in Figure 7.1 and Figure 7.2.
For the PTV, a larger discrepancy between PB and CC coverage is significantly corre-
lated with a smaller ROI volume (ρPTV = −0.77, pPTV < 0.001), while for the GTV and
ITV the correlation coefficient is less pronounced and not significant (ρITV = −0.43,
pITV = 0.08, ρGTV = −0.18, pGTV = 0.49). Large difference of Dmin, D99, Dmax and
D1 between PB and CC is significantly correlated with ROI volume for all three tar-
get ROIs GTV, ITV and PTV. There was considerable variability of the dose volume
parameters of GTV, ITV and PTV between patients, likely due to tumor volume and
position. As expected the differences were more pronounced for tumors completely
surrounded by lung tissue and not adherent to pleural or mediastinum tissues. For
example, the difference in average GTV relative volume covered by 60 Gy or more
was 3.5% for peripheral tumors compared to 6.1 % for centrally located tumors. Pre-
sumably, this is due to the fact that the density of the chest wall and mediastinal tissue
is closer to the density of water, than the low density lung tissue. Therefore the PB
algorithm, which assumes water density laterally, estimates dose more accurately in
tumors partially attached to denser tissue than in those surrounded mainly by air. In
one extreme case of a central tumor with very small volume, the GTV V60Gy was re-
duced from 100% to 26%, Dmean from 74.2 Gy to 57.9 Gy and D99 from 71.6 Gy to 49.9
Gy. The PTV coverage was tremendously reduced from 96% to 3.6%. The dose vol-
ume histograms (DVHs) of this patient are shown in Figure 7.3. Dose distributions
of this patient and another less extreme case with larger tumor volume close to the
posterior chest wall are shown in Figure 7.4. No correlation was found between tumor
movement (which was quantified by the ratio of ITV volume to GTV volume) and
difference in GTV coverage (Figure 7.1 bottom, right, ρ = 0.12, p = 0.63). However,
this result may be limited to this study and a more rigorous analysis is necessary to
evaluate the impact of tumor motion on dose distribution in general, for example by
performing a four dimensional (4D) dose calculation study similar to Guckenberger et
al. (Guckenberger et al., 2007).
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ROI Parameter PB CCre−calc CCcov CCclin
GTV V60Gy (%) 99.8 ± 0.9 86.6 ± 26.5 99.6 ± 1.0 99.4 ± 1.5
Dmean (Gy) 73.7 ± 1.6 67.0 ± 4.4 72.8 ± 1.5 72.5 ± 1.6
Dmin (Gy) 63.1 ± 11.0 51.4 ± 9.6 61.3 ± 8.5 59.5 ± 9.6
D99 (Gy) 67.9 ± 7.1 56.8 ± 7.6 65.5 ± 5.4 64.2 ± 6.3
Dmax (Gy) 76.8 ± 1.4 71.6 ± 4.0 76.6 ± 1.3 76.6 ± 1.3
D1 (Gy) 76.4 ± 1.4 71.3 ± 3.9 76.3 ± 1.3 76.4 ± 1.3
ITV V60Gy (%) 99.6 ± 1.7 79.8 ± 30.4 98.4 ± 4.3 97.3 ± 5.7
Dmean (Gy) 73.3 ± 1.7 64.8 ± 5.2 71.0 ± 2.1 70.6 ± 2.3
Dmin (Gy) 60.6 ± 12.4 47.7 ± 11.0 57.9 ± 11.7 56.3 ± 11.7
D99 (Gy) 66.0 ± 10.5 53.2 ± 9.9 62.1 ± 8.6 60.7 ± 9.4
Dmax (Gy) 77.0 ± 1.5 71.6 ± 4.0 76.6 ± 1.3 76.6 ± 1.3
D1 (Gy) 76.7 ± 1.4 71.1 ± 4.0 76.2 ± 1.2 76.2 ± 1.2
PTV V60Gy (%) 95.1 ± 1.9 55.7 ± 27.0 90.9 ± 12.5 85.5 ± 15.3
Dmean (Gy) 69.9 ± 1.3 60.0 ± 5.7 67.4 ± 2.6 66.6 ± 3.1
Dmin (Gy) 43.4 ± 4.9 35.8 ± 3.9 49.2 ± 4.4 46.4 ± 5.2
D99 (Gy) 55.0 ± 1.9 44.3 ± 5.3 56.7 ± 3.7 54.2 ± 4.5
Dmax (Gy) 77.0 ± 1.5 71.6 ± 4.0 76.6 ± 1.3 76.6 ± 1.3
D1 (Gy) 76.5 ± 1.4 70.7 ± 4.1 75.8 ± 1.2 75.8 ± 1.2
Lungs V20Gy(%) 7.6 ± 4.3 6.8 ± 4.2 9.6 ± 5.0 8.9 ± 4.9
V10Gy (%) 14.3 ± 5.7 13.4 ± 6.3 17.4 ± 6.6 16.3 ± 6.5
Dmean (Gy) 5.3 ± 2.1 5.0 ± 2.0 6.6 ± 2.3 6.1 ± 2.3
Heart Dmean (Gy) 3.0 ± 3.5 2.9 ± 3.5 3.6 ± 3.5 3.4 ± 3.5
Spinal cord Dmax (Gy) 8.3 ± 8.8 8.1 ± 8.5 10.9 ± 9.6 10.3 ± 9.6
Esophagus Dmax (Gy) 17.6 ± 9.7 16.9 ± 8.9 19.6 ± 10.6 19.3 ± 10.3
Table 7.2: Mean dose and volume parameters and standard deviations for targets and
organs at risk for pencil beam (PB) and collapsed cone (CC) calculations.
7.3.2 Pencil Beam Plan versus Clinical Collapsed Cone Plan (CCclin)
and Collapsed Cone Plan with Similar Coverage (CCcov)
For the GTV there was no statistically significant difference in Dmean, Dmin, Dmax, D99,
andD1 when comparing PB to the plan with similar coverage (CCcov). By design there
was no difference in coverage (V60Gy). For the PTV there was a significant difference
in Dmean, Dmin, D99 and D1 but not in terms of coverage and Dmax. In order to achieve
similar coverage, MUs delivered and field size in X and Y direction had to be ad-
justed. Total MUs and average field size in X and Y direction were significantly larger
in the CCclin and CCcov plans (p < 0.001, Table 7.3). Fields were more often adjusted
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Figure 7.1: Target coverage versus target volume for a) GTV, b) ITV and c) PTV. Figure
c) shows GTV coverage versus the ratio of ITV and GTV volume which is indicative
of tumor movement. The black markers indicate the original values calculated with
pencil beam (PB), while the red and green markers show the recalculated collapsed
cone (CCre-calc) patients with central tumors (red) and tumors attached to mediastinum
or pleura (green).
craniocaudally than laterally. In the LMU current clinical practice the enhanced CC
algorithm is used to calculate dose, and the field size is allowed to increase up to a
distance of 10 mm between the jaws and the outer PTV margin in BEV (compared to
5 mm in former plans calculated with PB) to achieve more adequate calculated GTV
coverage. The clinically acceptable plans CCclin therefore had acceptable GTV cover-
age that was not different from coverage calculated with the original PB. However,
CCclin plans had decreased Dmin and D99 for the GTV. The field size is usually not
increased enough to also achieve the same planned PTV coverage as with PB, espe-
cially in areas mainly consisting of air. Thus, by construction, PTV values do not reach
values of the original PB plan for CCclin plans.
For OARs, all evaluated parameters were significantly larger in the CCcov plan than
PB CCcov CCclin
Average relative change of total MU (%) - 5.0 ± 5.6 5.8 ± 5.9
Average field size X (cm) 4.6 ± 1.3 5.0 ± 1.3 4.9 ± 1.3
Average field size Y (cm) 6.5 ± 1.9 7.2 ± 1.9 6.9 ± 2.0
Table 7.3: Dose and volume parameters for targets and organs at risk for pencil beam
and collapsed cone calculations.
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Figure 7.2: D99 versus the total absolute volume for a) GTV, b) ITV and c) PTV. Figure
d) shows the maximal dose versus the total GTV volume. The black markers indicate
the original values calculated with pencil beam (PB), while the red and green markers
show the recalculated collapsed cone (CCre-calc) patients with central tumors (red) and
tumors attached to mediastinum or pleura (green).
PB and consequently in CCre-calc. This is due to the increased monitor units and field
sizes necessary to achieve similar calculated target coverage for the CCcov plan com-
pared to the PB plan. The results for the CCcov and CCre-calc plans imply that when
switching dose calculation algorithms from PB to CC without changing the criteria
for an acceptable treatment plan, the OARs will be exposed to increased dose. This
is because when using CC the same plan quality in terms of reported target coverage
(especially in the PTV) can only be achieved by increasing MUs and field size, which
leads to higher dose to OAR. Although the CC calculated dose is closer to the truly
delivered dose and thus preferable over PB, many OAR constraints originate from ex-
perience with PB. While some of the available recommendations for lung SBRT may
suggest adaptation of the dose prescription according to the type of dose-calculation
algorithm used that is not nearly always the case for clinical recommendations (Hurk-
mans et al., 2009).
The difference between dose estimates by using PB and CC in target structures is
especially pronounced in the PTV, because the PTV contains tumor tissue as well as
air in the planning CT and thus includes large variation of tissue density.
Our data is in the range of previously reported works by Haedinger et al. (Haedinger
et al., 2005), who found a decrease in Dmean of 11.2 % whereas 14.2 % was found in this
study. However, a much more drastic change in average PTV coverage of 39.4 vol-
ume % was found compared to 7.1 volume % found by Haedinger et al., who used the
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Figure 7.3: Dose volume histograms of GTV, PTV, lungs, heart, spinal cord and esoph-
agus for a patient with extreme differences between PB and CC distributions. The
solid, dashed, dotted and dashed-dotted lines represent the PB, CCre-calc, CCcov and
CCclin plans respectively.
Helax-TMS treatment planning system. It is therefore essential to keep stressing the
importance of the choice of suitable dose calculation algorithms. Although there are a
variety of studies that have investigated implications of using PB type versus CC type
dose calculation algorithms, e.g. (Haedinger et al., 2005; Traberg Hansen et al., 2005),
most publications on the matter consider the PTV and clinical target volume (CTV)
mainly or exclusively. However, Guckenberger et al. (Guckenberger et al., 2007) have
shown that the 4D dose calculated over all breathing phases in the GTV is similar
to the dose in the GTV in one single phase for 3D-CRT plans (end-exhalation, end-
inhalation, or mid-ventilation phase). This means that the GTV may really be the rel-
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Figure 7.4: Sagittal, coronal and transversal CT view of two sample patients. The top
slices show the most extreme case (Patient 2) due to the small tumor volume, whereas
the bottom slices depict a less extreme case. Pencil beam (PB) is shown on the left
and the plans recalculated with collapsed cone (CCre-calc) on the right. The orange,
yellow, bright green, light green, light blue, medium blue, turquoise and dark blue
lines represent the 75 Gy, 67.5 Gy , 60 Gy, 52.5 Gy, 45 Gy, 37.5 Gy, 30 Gy and 15 Gy
isodoses, respectively.
evant ROI for evaluating such differences resulting from dose calculation algorithms
assuming that the fields are opened enough to allow coverage of the GTV in all phases.
The present study therefore also includes data for the GTV. Aarup and Dobler (Aarup
et al., 2009; Dobler et al., 2006) demonstrated discrepancies in mixed-density phantom
studies. They showed that PB algorithms tend to overestimate the target dose, while
CC and MC seemed to provide more reliable data compared to measurements. Latifi
et al. demonstrated that there was a significantly higher rate of reoccurrence when
SBRT plans were planned using a PB algorithm for dose calculation than if CC was
used (Latifi et al., 2014).
The performance of dose calculation algorithms in lung depends on the use of dif-
ferent patient models (Sikora et al., 2009) in order to account for target motion in the
presence of large density inhomogeneities (i.e. static CTs , average CTs, CTs with den-
sity overrides, maximum intensity projection) (Bradley et al., 2006; Pan et al., 2013).
For the purpose of this study, dose calculation was performed only on a single static
planning CT, which is the current clinical practice at LMU Munich for lung SBRT treat-
ment planning using OTP. Furthermore, it should be noted that both the quality of the
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beam model and the TPS-specific implementation of the head model can influence the
performance of different dose calculation algorithms and impact the calculated dose
distribution. The results obtained in this study may therefore be specifically useful for
OTP users. For the purpose of this study PB and CC beam models were used that were
carefully verified with respect to base data measurements prior to clinical use at LMU
Munich.
The large discrepancies resulting from use of different dose calculation algorithms
are of special importance when multi-institutional studies are performed. A compar-
ative planning study for the JCOG 0403 protocol showed notable differences between
the participating institutions for Dmax, Dmin, D95, and the homogeneity index of the
PTV, although target definitions and target dose constraints were the same. These
inter-institutional deviations were mainly attributed to the different choice dose cal-
culation algorithms used in the institutions (Matsuo et al., 2007). Even if only CC al-
gorithms are used, their quality may depend on the exact implementation of the algo-
rithm in the treatment planning system, and be specific to the release version (Huang
et al., 2013; Vanderstraeten et al., 2006). The use of a wide variety of dose prescription
modes in stereotactic radiotherapy leads to additional in-transparency when compar-
ing data (Onishi et al., 2007).
More recently started studies require tissue density heterogeneity correction. For
Radiation Therapy Oncology Group (RTOG) 0236, SBRT conformal treatment plans
that met the dosimetric compliance criteria recommended for RTOG 0813 were gener-
ated using XiO/superposition, and then recalculated using MC. Tissue density hetero-
geneity correction was applied in the initial calculations. V20Gy increased on average
by 18% in the MC plans (Li, Galvin, Harrison, Timmerman, Yu and Xiao, 2012).
Although CC algorithms predict dose more accurately than PB algorithms, they
can nevertheless deviate from measured dose and dose calculated with MC. Several
studies investigated deviations of MC algorithms from measured dose or dose calcu-
lated with MC, e.g. (Krieger and Sauer, 2005; Kry et al., 2013; Vanderstraeten et al.,
2006). Krieger et al. (Krieger and Sauer, 2005) and Kry et al. (Kry et al., 2013) found
good agreement between MC and measured dose. Thus, in order to fully evaluate
the implications of using PB and CC algorithms in the clinic, a comparison with MC
would be necessary.
7.4 Conclusion
The use of different calculation algorithms leads to significant changes not only in
dose, but also in field size and MUs delivered, if similar target coverage criteria are ap-
plied for treatment planning. This has to be taken into account for treatment planning
and comparison of data concerning side effects as well as local control in radiother-
apy of intrapulmonary lesions. Using CC improves the accuracy of dose calculation
in the tumor. However, attempting to cover the parts of the PTV and ITV that mainly
consist of air, caused a higher strain on the lung and OARs in this study. In cases with
borderline acceptable OAR exposition, OAR plans should be evaluated cautiously. If
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data concerning safety margins, OAR limits, maximum or mean dose and PTV/ITV
coverage of radiotherapy plans in stereotactic radiotherapy are compared, it is of in-
terest to state which dose calculation algorithm was used. Future projects will include
comparison of the resulting CC and PB dose distributions to the MC gold standard,
as dose calculated with CC itself can deviate from measured values. Also evaluation
of accumulated 4D dose may be necessary to estimate the actual increase of tumor
control probability that can be achieved by trying to obtain PTV coverage with CC.
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Since the beginnings of radiation therapy, sparing healthy tissues from the harmful
effects of the radiation used to destroy tumor cells has been a vital component of the
treatment process. Therefore the need to accurately predict the probability of side
effects already became apparent early in the evolution of radiotherapy.
Normal tissue complication probability (NTCP) models provide a probability of a
patient experiencing side effects as a function of the dose received by the respective
structure. Reliable NTCP models can be useful tools in clinical practice for evaluating
treatment plans. Today, a multitude of studies have been undertaken to model NTCP
for different treatment sites, structures and endpoints. Yet many challenges remain in
the field of NTCP modelling.
This thesis aimed at exploring challenges and uncertainties in NTCP modelling, as
well as evaluating how organs at risk dose estimates compare. The choice of treat-
ment technique was shown to influence NTCP model parameters, and that models
derived from patients treated with different treatment techniques have limited cross-
applicability. The use of NTCP models for patients treated with hypofractionated ra-
diation therapy (HFRT) was also investigated and discussed. It was determined that
parameters for HFRT differ from values reported for standard fractionated radiation
therapy (SFRT) in the literature, when the conventional linear quadratic (LQ) model
was used to account for fractionation. Furthermore, an alternative model for correct-
ing dose for fractionation effects was investigated, which has the potential to describe
HFRT and SFRT with the same set of model parameters. Finally, the effects of different
dose calculation algorithms on dose to regions of interest were explored, since NTCP
models depend on the accuracy of the underlying dose distributions. It was shown
that calculated dose can differ significantly between algorithms.
Cross-Applicability of Normal Tissue Complication Prob-
ability Models Between Treatment Techniques
The results of this work indicate that NTCP models cannot generally be extrapolated to
treatment techniques they were not derived from. This was demonstrated by an NTCP
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modelling study using patients treated for prostate cancer. Optimal NTCP model pa-
rameters for gastrointestinal (GI) toxicities derived from three dimensional conformal
radiation therapy (3D-CRT) patient data and intensity modulated radiation therapy
(IMRT) patient data were calculated and compared. It was shown that the models
derived from the two populations were not cross-applicable. These results were unex-
pected, since NTCP model parameters for an endpoint should ideally not depend on
the treatment technique.
Comparison of NTCP models derived from different populations is generally dif-
ficult because of inherent differences in confounding patient characteristics of the pa-
tient cohorts. This study is the first to systematically compare NTCP models for 3D-
CRT and IMRT patients. A novel approach was followed with the use of propensity
score matched pair analysis between the 3D-CRT and IMRT patients on multiple pa-
tient characteristics. This allowed for a more fair comparison of the two groups, and
reduction of potential confounding bias.
Subsequent investigations into the source(s) of discrepancies between optimal model
parameters for the two groups ruled out differences in follow-up time, imaging modal-
ities used, known patient characteristics and errors of planned versus delivered dose.
Other potential sources of the discrepancies could be related to the scoring of toxicity,
confounding patient characteristics not accounted for by matched pair analysis, and
insufficiency of the models themselves. It is possible, albeit unlikely, that the patient
characteristics that were not recorded were responsible for the different model param-
eters observed for 3D-CRT and IMRT patients and observer bias in toxicity scoring
could not be ruled out retrospectively. Finally, the models themselves may not be ca-
pable of describing the two populations with the same model parameters. The models
used in this work are phenomenological models rather than mechanistic, and although
they may work well when fitted to data from one cohort, are potentially not capable
of describing other patient cohorts. Furthermore, they are based on dose volume his-
tograms which omit spatial information contained in the 3D dose distribution that
may be necessary for accurate NTCP modelling.
As part of this study, a set of optimal NTCP parameters for GI toxicities in IMRT pa-
tients was determined. Although NTCP for GI toxicities in 3D-CRT has been studied
intensively, there are few studies on NTCP models for GI toxicities in IMRT patients.
This is due to limited data available on patients treated with IMRT, and the low inci-
dence of GI toxicities in the IMRT population. Yet despite the lack of validated NTCP
models, IMRT is increasingly used in the clinic. Therefore, the IMRT parameters pre-
sented in this thesis provide a basis for future work, however, they do not constitute
clinical recommendations without validation in other patient cohorts. Fortunately,
the NTCP model parameters derived from the 3D-CRT data overestimated NTCP for
IMRT patients, and thus do not pose a risk of increasing side effects when applied to
IMRT patients.
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plication Probability Models
This work also applied NTCP modelling to radiation pneumonitis in HFRT lung can-
cer patients. The LQ model was used to correct for the fractionation scheme and the
optimal NTCP model parameters were determined. However, the resulting HFRT pa-
rameters differ from the reported parameters for SFRT in the literature. The actual op-
timal model parameters for HFRT suggest that HFRT patients experience pneumonitis
at higher doses than SFRT patients. This demonstrates that NTCP models are not cross
applicable for different fractionation schemes, even if accounting for fractionation us-
ing the LQ model.
In addition to the LQ model, the low dose hyperradiosensitivity (LDHRS) model
was used to account for hypofractionation. The LDHRS model offers a biological ex-
planation for the observed decrease in incidence of toxicities seen in the HFRT pa-
tients. The LDHRS model can potentially be used to find a common NTCP model
for radiation pneumonitis in HFRT and SFRT lung cancer patients that describes both
populations with the same model parameters. However, further data are needed to
confirm this in the future. This was the first study to use the LDHRS model for NTCP
modelling and it was shown that it is feasible to use the model for modelling NTCP
for radiation pneumonitis in HFRT of the lungs.
Furthermore, NTCP model parameters for chest wall toxicities including chest wall
pain, rib fractures and myositis were determined and discussed in this thesis. These
toxicities occur frequently in patients who underwent lung stereotactic body radiation
therapy (SBRT), and there are no published studies which investigate this to the best
of the author’s knowledge. Since SBRT is becoming a standard treatment method for
certain forms of lung cancer, it is important to establish a predictive model in order to
minimize the morbidity of treatment.
The Impact of Dose Calculation Algorithms on Estimated
Dose
In this thesis, the choice of dose calculation algorithm is shown to significantly impact
dose volume parameters for both the target volumes and OARs. This is especially true
for non-homogeneous tissues. Specifically, using Collapsed Cone (CC) to recalculate
dose in lung plans created with pencil beam (PB) can lead to drastic differences in
planned dose for regions of interest. When attempting to achieve the same coverage
criteria with CC that were achieved with PB, field sizes and monitor units had to be
significantly adjusted. These differences could undoubtedly lead to differences in pa-
rameters for tumor control probability (TCP) and NTCP models. Thus, the studies in
this thesis demonstrate the importance of stating the dose calculation algorithm when
presenting NTCP model parameters, especially in the lung. Furthermore, it indicates
the importance of using dose calculation algorithms that model scattering more accu-
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rately, such as CC or Monte Carlo for calculation of dose distributions used in NTCP
modelling for lung radiation therapy.
Final Remarks
The findings in this thesis show that NTCP models are sensitive to treatment technique
and fractionation. They also show that the choice of dose calculation algorithms can
significantly alter dose to regions of interest and will thus have an impact on NTCP
models derived from such dose distributions. Therefore, NTCP models should be
carefully validated before extrapolating the model parameters to other populations
that differ in treatment technique, fractionation scheme and the dose calculation algo-
rithm used. This becomes especially relevant as the field of radiation therapy rapidly
evolves, creating new treatment approaches and incorporating new technologies.
Despite these limitations, NTCP models are invaluable tools in the field of radia-
tion oncology. They provide evidence based, data-driven, quantitative, and objective
metrics that can guide clinicians in identifying the risk of side effects. This informa-
tion, together with TCP, can provide the clinical team with a risk and benefit estimate
of a given treatment plan. The NTCP models derived in this work for GI toxicities in
IMRT patients, and pneumonitis and chest wall toxicities in lung SBRT patients, have
helped create clinical guidelines for constraints to OARs in these types of treatment.
In the future, research pertaining to NTCP modelling may focus on studies aim-
ing to further investigate sources of model uncertainties, and extend the models such
that they can be adjusted to individual clinical scenarios, including the treatment tech-
nique, fractionation and other factors. When applied appropriately, NTCP models are
undoubtedly a crucial tool in radiation therapy, with great potential to improve treat-
ment outcomes, minimize side effects and improve the patient’s quality of life.
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